Drug, bio-affecting and body treating compositions inventions 11/05

20050261165 - Methods of reducing microbial resistance to drugs: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity...

20050261162 - Pharmaceutical composition for preventing and treating cancer and treating an inflammation: The present invention relates to a pharmaceutical composition preventing cancer and treating cancer and inflammation, which is characterized in that including xanthorrhizol as an active principle. Xanthorrhizol not only inhibits mutagenesis and tumor formation, and enhances the activity of detoxification enzyme of carcinogen, induces apoptosis of cancer cell, and suppresses...

20050261163 - Pharmaceutical products, preparation and uses thereof: A pharmaceutical product comprising at least one therapeutic agent, whereby a unit dose of said therapeutic agent as provided by said pharmaceutical product can be administered to a patient during the passage of said therapeutic agent through the gastrointestinal tract of the patient, wherein said therapeutic agent is characterised as...

20050261164 - Remedy for urinary frequency and urinary incontinence: A composition for treating frequent urination and/or urinary incontinence comprising a compound having an activity to inhibit Na+/H+ exchange transporter or its pharmaceutically acceptable salt as an active ingredient....

20050261161 - Stable crystals of pyrrole compound: The present invention is constituted with crystal of 2-amino-3-cyano-4-methyl-5-(2-fluorophenyl)pyrrole, which show diffraction peaks at diffraction angles (2θ±0.2 degree) of 10.3 degree, 14.3 degree, 15.5 degree, 15.9 degree, 25.1 degree and 25.7 degree in a powder X-ray diffraction spectrum, and also show absorption peaks at wavenumbers (cm−1, ±0.2%) of 3373, 3322,...

20050261166 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20050261167 - Compositions for sleeping disorders: Provided herein is a composition that contains an effective amount of one or more compounds for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder and using the composition....

20050261168 - Novel formulations: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog....

20050261170 - Folate conjugates and complexes: Disclosed are conjugates and complexes that include a folate receptor ligand and one or more therapeutic molecules, such as onconase or a variant thereof such as rapLR1. The conjugates and complexes may be useful as primary therapeutic agents, which may be administered with additional therapeutic or diagnostic agents. Also disclosed...

20050261169 - Peptide and peptide mimetic derivatives having integrin inhibitor properties iii: and salts thereof as integrin inhibitors for the treatment of diseases, defects and inflammation caused by implants and of osteolytic diseases, such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, and for the acceleration and strengthening of the integration process of the implant or of the biocompatible surface into the tissue....

20050261172 - Agents and methods for promoting bone growth: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length...

20050261171 - Combination cancer therapy: The present invention relates to novel compositions comprising, (i) at least one of Taxol, Taxotere, bleomycin, carmustine, carboplatin, and doxorubicin; and (ii) MGd, a compound of Formula I. The present invention also relates to and methods of using said compositions to treat Cancer....

20050261173 - Antifungal parenteral products: Parenteral pharmaceutical formulations containing an echinocandin antifungal compound and an aqueous solvent are provided, wherein the formulation includes ethanol, for example about 20% w/v ethanol. The parenteral pharmaceutical formulation may further include one or more additives, such as a stabilizing agent, buffer or tonicity agent. The parenteral pharmaceutical formulations are...

20050261174 - Insecticidal activity of a cyclic peptide: A cyclic peptide isolated from an extract of the bark of a Madagascan plant, having a structure of formula (I), has insecticidal activity....

20050261178 - Co-administration of cg250 and il-2 or ifn-alpha for threating cancer such as renal cell carcinomas: A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method...

20050261181 - Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells: Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk...

20050261176 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell...

20050261177 - Compound: This invention relates to new polypeptide compound represented by the following general formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to...

20050261190 - Fas associated factor 1: The present application describes a Fas associated Factor 1 protein and fragment thereof that bind Hsc70/Hsp70, ubiquitinated protein and valosin containing protein....

20050261188 - Genes encoding proteins with pesticidal activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding δ-endotoxins having pesticidal activity against insect pests. The invention further provides mutagenized nucleic acids that have been modified to encode pesticidal polypeptides such as endotoxins having improved pesticidal activity and/or altered pest specificity....

20050261184 - Method for treating glaucoma: A method for reducing intraocular pressure and increasing outflow facility from an eye of a subject having glaucoma includes the step of providing in the trabecular meshwork of the eye an amount of caldesmon effective to reduce intraocular pressure and increase outflow facility....

20050261187 - Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy: The present invention relates to compositions and methods relating to MEK5 and its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its role molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy. In particular, inhibition of...

20050261189 - Methods of promoting cardiac cell proliferation: The present invention provides novel methods and compositions for promoting proliferation and/or regeneration....

20050261191 - Ngal for reduction and amelioration of ischemic and nephrotoxic injuries: Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective...

20050261192 - Novel polypeptide and its dna: It is intended to construct a screening method, etc. for searching for compounds which are capable of binding to apolipoprotein A-I and thus promote or inhibit the binding of a cubulin fragment to apolipoprotein A-I, and provide preventives or remedies containing compounds obtained by the above screening method, etc. These...

20050261186 - Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules....

20050261183 - Pthrp-derived modulators of smooth muscle proliferation: The present invention relates to the use of mutants of parathyroid hormone-related protein, to treat disorders associated with smooth muscle cells, and to inhibit the cellular activation and proliferation thereof. The method can be employed in diverse tissues to effect therapeutic and prophylactic relief for disorders and diseases manifested by...

20050261175 - Scf antibody compositions and methods of using the same: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed....

20050261185 - Therapeutic proteins: The present invention relates to a method for the treatment of a medical condition associated with obesity and/or insulin resistance, comprising administering to a subject in need thereof an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2 to 10,...

20050261182 - Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin: Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin....

20050261180 - Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions: Methods for treatment of inflammatory and fibrotic conditions in vivo using UG is disclosed. Methods for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG are also disclosed. Compositions containing UG, optionally containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are...

20050261179 - Vasoregulating compounds and methods of their use: Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock,...

20050261193 - Antimicrobial theta defensins and methods of using same: The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can...

20050261196 - Myosin light chain kinase inhibitors and methods of use: Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use....

20050261195 - Process for preparing lh-rh derivatives: A process for the preparation of LH-RH derivatives, characterized by subjecting a solution of an LH-RH derivative to both treatment with a synthetic methacrylic resin adsorbent and that with a synthetic aromatic resin adsorbent. According to this process, the formation of by-product impurities including racemates of LH-RH derivatives can be...

20050261194 - Use of thymulin-like peptides for making pain-relieving medicines: The present invention relates to the utilization of peptide analogues of thymulin that are inactive relative to the immune system, not comprising zinc and having anti-pain activity, for manufacturing a medicine for the treatment of pain....

20050261197 - Coffee bean extract, method of extraction and composition containing the same: A composition containing genistein, flavionic acid, diadzien, diadzin, and a peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine, as well as pharmaceutical compositions prepared from such compositions possessing anti-inflammatory activity, and a method for isolating each compound and producing such a composition. A heating, extracting and condensing system that efficiently recovers...

20050261201 - Method of reducing c-reactive protein using growth hormone secretagogues: The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event...

20050261199 - Pharmaceutical composition comprising a retro-iverso isomer peptide: The present invention provides a pharmaceutical composition comprising a peptide selected from the group consisting of D-Pro D-Tyr D-Val D-Val, D-Pro D-Tyr D-Val, and D-Leu D-Thr D-Val as an active component. The composition of the present invention has great efficacy in lowering serum triglyceride levels....

20050261202 - Sensitization to another anticancer therapy and/or amelioration of a side effect of another anitcancer therapy by treatment with a gst-activated anticancer compound: A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated...

20050261198 - Sulfur-containing proanthocyanidin oligomer compositon and process for producing the same: Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active...

20050261200 - Tri-peptide hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned...

20050261203 - Azabicyclo-octane inhibitors of iap: X1 and X2 are independently O or S; L is a bond or —C(X3)—, —C(X3)NR12, —C(X3)O— wherein X3 is O or S and R12 is H or R1; R1 is alkyl, a carbocycle, carbocycle-substituted alkyl, a heterocycle or heterocycle-substituted alkyl, wherein each is optionally substituted with halogen, hydroxyl, mercapto, carboxyl,...

20050261204 - Novel use of peptide compounds for treating dyskinesia: The present invention is directed to the use of a class of peptide compounds for treating primary or/and secondary dyskinesias such as tardive dyskinesia....

20050261205 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in...

20050261206 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in...

20050261207 - Glucose-based compounds with affinity to p-selectin: The present invention relates to certain glucose-based compounds that have an affinity to P-selectin. Further, the invention relates to the use of these glucose-based compounds for the preparation of pharmaceutical compositions for the treatment of disorders associated with P-selectin, to conjugates, pharmaceutical carriers and drug delivery systems comprising said compounds,...

20050261208 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and...

20050261209 - Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein: in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance...

20050261210 - Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders: The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI...

20050261211 - Process for preparing substituted benzimidazole compounds: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity....

20050261235 - 2' ,5' -oligoadenylate analogs: wherein m is 0 or 1; n is 0 to 2; R1 represents an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to...

20050261228 - Antisense modulation of interleukin 12 p35 subunit expression: Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment...

20050261214 - Complexes for transferring substances of interest into a cell: The present invention concerns new polar compounds, complexes and compositions comprising them, wherein said compound comprises: (i) a polar headgroup spacer, (ii) at least one hydrophobic moiety, and (iii) at least one hydrophilic polymer, and wherein said polar headgroup spacer is coupled to said hydrophobic moiety and to said hydrophilic...

20050261221 - Compositions and methods for enhanced delivery of compounds via transfection complexes: The present invention relates to compositions and methods for enhanced delivery of compounds (e.g., drugs, nucleic acids, peptides, etc.) via transfection complexes (e.g., liposomes). In particular, the present invention utilizes agents that synergistically enhance the ability of a transfection complex to deliver a compound to cells or tissue....

20050261229 - Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the...

20050261234 - Gfap-based gene therapy for treatment of retinal diseases: Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid...

20050261231 - Hepatocyte growth factor nucleic acid sequence to enhance musculocutaneous flap survival: The present invention relates to the use of growth factors in improving tissue survival. In particular, the invention describes methods for enhancing organ transplant, musculocutaneous flap or skin graft survival by administering a nucleic acid sequence encoding hepatocyte growth factor....

20050261230 - Method for the prophylaxis and/or treatment of medical disorders: The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on...

20050261226 - Methods and compositions for the treatment of cancer with oligonucleotides directed against egr-1: Oligonuclotides, compositions and methods for modulating the over-expression of EGR-1 in cancer cells. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Egr-1. Methods include using these compounds for modulation of Egr-1 expression in cancer cells in which Egr-1 is over-expressed for the treatment of cancer....

20050261215 - Methods and immune modulatory nucleic acid compositions for preventing and treating disease: This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly...

20050261224 - Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not...

20050261233 - Modulation of glucose-6-phosphatase translocase expression: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders....

20050261216 - Modulation of nanos 1 expression: Compounds, compositions and methods are provided for modulating the expression of Nanos 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Nanos 1. Methods of using these compounds for modulation of Nanos 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Nanos 1...

20050261217 - Modulation of pumilio 1 expression: Compounds, compositions and methods are provided for modulating the expression of Pumilio 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Pumilio 1. Methods of using these compounds for modulation of Pumilio 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Pumilio 1...

20050261232 - Non-natural ribonuclease conjugates as cytotoxic agents: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such...

20050261227 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof,...

20050261213 - Nucleic acid compositions and methods for use: Polynucleotide compositions encoding a tumor antigen antigenic determinant and optionally including a nucleic acid adjuvant are disclosed. The compositions are useful for prophylaxis or treatment of cancer....

20050261218 - Oligomeric compounds and compositions for use in modulation small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment...

20050261222 - Oligoribonucleotides for the treatment of irritative or inflammatory skin symptoms through rna interference: The invention is a double-stranded oligoribonucleotide or a physiologically compatible salt thereof, which is capable of inducing the degradation of mRNA of one of more structures involved in inflammation or irritation of the skin. The invention is also cosmetic or therapeutic compositions comprising one or more such double-stranded oligoribonucleotide and...

20050261225 - Peptides that deliver antisense oligonucleotides which downregulate protein expression in cells: The present invention provides a peptide that can complex with an oligonucleotide, e.g. an antisense oligonucleotide, and deliver it into a cell. The present invention also provides compositions comprising a complex of such a peptide and an oligonucleotide and methods of delivering an oligonucleotide into a cell and of inhibiting...

20050261223 - Rip140 regulation of glucose transport: Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat....

20050261219 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin...

20050261212 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering rna: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with Alzheimer's disease. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against NOGO...

20050261220 - Tumor treating combinations, compositions and methods: The invention relates to compositions and methods of use in the treatment of tumors in animals. The invention is particularly concerned with the combination of HIF inhibiting agents, specifically antisense HIF-1, with antiangiogenic agents....

20050261236 - Agonists of a2a adenosine receptors for treatment of diabetic nephropathy: The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor....

20050261238 - Method for increasing muscle mass and strength through administration of adenosine triphosphate: The present invention is directed to compositions having an effective amount of Adenosine Triphosphate (“ATP”) sufficient to effect intracellular and extracellular concentrations of ATP in a mammal to improve anaerobic exercise capacity by increasing muscle size and/or strength and methods for using the same. Preferably, a gastric acid secretion inhibitory...

20050261237 - Nucleoside phosphonate analogs: The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20050261239 - Use of atp for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue: The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS)...

20050261240 - Carrageenan based antimicrobial compositions: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more carrageenans, including lambda carrageenan. Also disclosed are methods for making and using the compositions....

20050261241 - Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or...

20050261243 - Antiprostaglandins for the treatment of ocular pathologies: Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise flurbiprofen in a concentration and dose suitable for treating ocular...

20050261242 - Pharmaceutical compounds: r

20050261244 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity....

20050261245 - Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds...

20050261246 - Methods for treating inflammatory and autoimmune diseases: The present invention provides methods for treating inflammatory conditions, rheumatoid diseases, autoimmune conditions, and conditions associated with bone loss, comprising administering to a subject with an inflammatory condition an amount effective to treat the condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′ phosphate and pancratastatin-3′,4′...

20050261249 - Antisense composition and method for treating cancer: A method and composition for of treating cancer, and in particular, for arresting the progression of a solid or primary cancer to a more invasive, metastatic state, are disclosed. The composition includes a substantially uncharged antisense compound (i) having a nuclease-resistant backbone, (ii) capable of uptake by target cancer cells...

20050261247 - Inhibition of jun kinase: Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin...

20050261248 - New-4-pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives: This invention is directed to selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy....

20050261251 - Antiviral agents and methods of treating viral infections: The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds....

20050261250 - Compositions and methods for inhibiting bone resorption: Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D3 suitable for once-weekly dosing. Compositions and methods of the...

20050261252 - Lpa receptor agonists and antagonists and methods of use: The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA...

20050261253 - Kinase inhibitory phosphonate analogs: The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20050261254 - Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation: A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate...

20050261255 - Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from...

20050261256 - Treatment of icu-associated hypocalcemia with vitamin d compounds: The present invention relates to a method of improving intensive care unit (ICU)-associated hypocalcemia in a mammal by the administration of a vitamin D compound, or other compounds exhibiting vitamin D-like activity, to the mammal for a sufficient period of time to improve or restore the serum calcium levels of...

20050261257 - Compositions for treating or preventing cardiovascular disease: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular...

20050261258 - Methods and compositions for the non-surgical removal of fat: Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions...

20050261259 - Phytosterol and/or phytostanol derivatives: The present invention relates to a phytosterol and/or a phytostanol ester compound produced from the reaction of a phytosterol and/or a phytostanol with a polyunsaturated fatty acid (PUFA), wherein the polyunsaturated fatty acid has from 18 to 22 carbon atoms and at least three carbon-carbon double bonds. Processes for producing...

20050261260 - Combination of a cdk inhibitor and mitoxantrone: A first aspect of the invention relates to a combination comprising a CDK inhibitor and mitoxantrone. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and mitoxantrone as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the...

20050261261 - Eplerenone drug substance having high phase purity: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a...

20050261263 - Benzoquinone ansamycins: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer...

20050261262 - Rifamycin derivatives effective against drug-resistant microbes: Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently...

20050261264 - Rare-earth ternary complex: wherein M is a rare earth atom; n1 is 2 or 3; n2 is 2, 3, or 4; Rf1 and Rf2 are the same or different and are each a aliphatic group having 1 to 22 carbon atoms and containing no hydrogen atoms, an aromatic group containing no hydrogen atoms,...

20050261265 - Modulating cellular senescence by amphiphysin-1: The present invention relates to nucleic acid sequences and proteins involved in senescence and particularly, to nucleic acid sequences and proteins including amphiphysin and caveolin involved in cellular senescence and their use....

20050261266 - Radiopharmaceutical and methods of synthesis and use thereof: A novel group of apomorphine derivatives are provided that are well suited as radioimaging agents upon incorporation of radionuclides. Through reaction of D ring sites, the less reactive sites of the apomorphine A ring is modified in ways previously unattainable....

20050261267 - Pharmaceutical formulation: Pharmaceutical formulations comprising amoxycillin and clavulante in a ratio of from 10:1 to 20:1 are of use in the emperic treatment of infections potentially caused by DRSP....

20050261268 - Aminotriazole compounds useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders....

20050261269 - New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them: e

20050261270 - Modified beta-lactamases and uses thereof: A tool that can screen bacteria for β-lactamases against a panel of various antibiotics is desirable. A biosensor incorporating an indicator molecule into β-lactamases may achieve this purpose, but it requires that the attached indicator molecule must not impair the binding affinity of the protein to a great extent to...

20050261271 - Dipeptidyl peptidase inhibitors: t

20050261272 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase:

20050261273 - Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors: The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein....

20050261274 - Lactams substituted by cyclic succinates as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of...

20050261275 - Therapeutic combination: This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including...

20050261276 - Novel sulphones for inhibition of gamma secretase: i

20050261277 - Pentacyclic oxepines and derivatives thereof, compositions and methods: The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC—OCO(C1-C6 alkyl), or —OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), —OSO2(C2-C6 alkyl)or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or...

20050261278 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions....

20050261279 - Compounds: R7 represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and...

20050261280 - Stabilized antihistamine syrup: An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, such as a salt of ethylenediaminetetraacetic acid....

20050261281 - Pharmaceutical compounds: an ether group of formula —(CH2)—O—(CH2)v—R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)-Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)-Z′, Z′ being as defined...

20050261282 - Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines: The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism....

20050261283 - Methods and compositions for the treatment of graft failure: The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate) to inhibit the biological activity of the PDGFR....

20050261284 - Diazinopyrimidines: e

20050261285 - Tetrahydropyran derivatives and their use as therapeutic agents: The present invention relates compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R15 and R16 represent a variety of substituents; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or...

20050261287 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors: e

20050261286 - Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament:

20050261288 - Tetracyclic lactam derivatives and uses thereof: The present invention relates to Tetracyclic Lactam Derivatives, compositions comprising an effective amount of a Tetracyclic Lactam Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease,...

20050261289 - 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide: which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine,...

20050261290 - Novel compounds of proline and morpholine derivatives: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R1, R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is...

20050261291 - 1,2-di(cyclic)substituted benzene compounds: e

20050261293 - Compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,...

20050261292 - Pharmaceutical composition containing n-sulfamoyl-n'-arylpiperazines for the treatment or inhibition of obesity and related conditions: s

20050261295 - Pyrimidine as plk inhibitors:

20050261294 - Substituted heteroaryl derivatives, compositions, and methods of use: The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor...

20050261296 - Indole, azaindole and related heterocyclic n-substituted piperazine derivatives: e

20050261297 - Nitrogen-containing heterocyclic compound: As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can...

20050261299 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors:

20050261300 - Liquid pharmaceutical formulations containing 3.7-diazabicyclo[3,3,1]nonane compounds and methods of treatment relating to arrhythmic events: A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion...

20050261298 - Methods of treating conditions associated with an edg-7 receptor: In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the...

20050261301 - Therapeutic ion channel blocking agents and methods of use thereof: Various divalent ligands based on khellinone derivatives are described. These derivatives can be useful in the modulation of potassium channel activity in cells, including among others Kv1.3 channels found in T-cells. The compounds may also be useful in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis....

20050261302 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme and their therapeutic application: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic...

20050261303 - N-phenyl-(2r,5s) dimethylpiperadine derivative: The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and...

20050261305 - Cyclic protein tyrosine kinase inhibitors: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders....

20050261304 - Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders: The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation....

20050261306 - Anti-neurodegenerative agents: The present invention provides methods for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Huntington's disease, Parkinson's disease, Alzheimer's disease, dementia after cerebral vascular disorder, dementia accompanied by other neuronal degeneration. The present invention provides methods for treating or preventing neurodegenerative diseases comprising...

20050261307 - Inhibition of fgfr3 and treatment of multiple myeloma: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having...

20050261308 - Quinolinone derivatives and uses thereof: t

20050261309 - Imidazole compounds: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions....

20050261310 - Piperazinylpiperidine derivatives as chemokine receptor antagonists: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as...

20050261311 - Piperizinones as modulators of chemokine receptor activity: e

20050261312 - Pharmaceutically acceptable inorganic and organic salts of 5-methylpyrazine-2-carboxylic acid-4-oxide: Methods for the preparation of pharmaceutically acceptable organic or inorganic salts of 5-methylpyrazinecarboxylic acid-4-oxide esters including tris(hydroxymethyl)aminomethanol, N,N-dimethylethanolamine, N-methyl-D-glucamine, L-Lysine, L-arginine, Na, K, Ca and Mg. The esters of 5-methylpyrazinecarboxylic acid-4-oxide are oxidized in aqueous hydrogen peroxide at a pH of 2.5 to 7 in the presence of a catalyst...

20050261313 - Substituted alkylamine derivatives and methods of use: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention...

20050261314 - 7-amino triazolopyrimidines for controlling harmful fungi: The invention relates to 7-amino triazolopyrimidines of formula (I), in which the substituents have the following meanings: R1, R2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl; or 5-membered or 6-membered heterocyclyl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom;...

20050261316 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea....

20050261315 - Amide derivatives as kinase modulators: The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of amide compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects....

20050261317 - Inhibitors of human phosphatidylinositol 3-kinase delta: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K5, while not significantly inhibiting activity of other PI3K...

20050261318 - Protein kinase inhibitors: Disclosed are compounds which inhibit or modulate the activity of protein kinases and pharmaceutical compositions containing such compounds. The disclosed compound contain two or more ligand moieties covalently linked together by one or more linking groups. Such compounds are useful for treating diseases or medical disorders mediated by protein kinases....

20050261319 - Novel 2-amino-4-quinazolinones and 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properties: The present invention relates to compounds according to the general formulas (I) and/or (Ia), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds...

20050261320 - Compounds and methods for the treatment of cancer: (−)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (−)-OddC) or its derivative and its use to treat cancer in animals, including humans....

20050261322 - Hiv integrase inhibitors: Compounds of the present disclosure are spirocycle-substituted pyrimidinecarboxamides. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating HIV infection and AIDS....

20050261323 - Medical uses of novel carbamate-substituted pyrazolopyridine derivatives: wherein R1 is H or a di-C1-6-alkylaminocarbonyl radical, and R2 is a radical of the formula —O—C(X)—NR3R4 wherein X is O or S. The compound may also be administered in combination with at least one organic nitrate or NO donor, or in combination with at least one compound which inhibits...

20050261321 - Substituted organosulfur compounds and methods of using thereof: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions....

20050261324 - Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia,...

20050261327 - 2-(bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway....

20050261325 - Gamma-aminoamide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor...

20050261326 - Metabolites of ecteinascidin 743: The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as “ETM” followed by a numeric value which represents the approximate molecular weight. Three compounds have been identified to date, namely ETM 305, ETM...

20050261328 - Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents: A pharmaceutical composition useful in the treatment of functional bladder disorders comprising an antimuscarinic agent and a beta-3-adrenoceptor agonist is described....

20050261329 - Opioid and opioid-like compounds and uses thereof: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage....

20050261330 - Derivatives of 2,2,4-trisubstituted tetrahydrofuran an antifungal agents: The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans....

20050261331 - Substituted pyrrolopyridines: There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk....

20050261332 - Sulfonamides and uses thereof: e

20050261333 - Use of and some novel imidazopyridines: The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is...

20050261334 - Bis-pyridino containing compounds for the use in the treatment of cns pathologies: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for...

20050261335 - Carvedilol formulations: This invention relates to pharmaceutical formulations of carvedilol in which a solubilising agent is used to solubilise carvedilol in oils and/or lipids, and methods of of using these formulations to treat hypertension, congestive heart failure and angina....

20050261337 - Substituted quinoline derivatives: The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:...

20050261336 - Use of quinoline derivatives with anti-integrase effect and applications thereof: The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase-inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular for...

20050261338 - Beta2-adrenergic receptor agonists: Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor....

20050261339 - Pyrazole compound and medicinal composition containing the same: V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom,...

20050261343 - Anthranilamides and their use as pharmaceutical agents: Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described....

20050261342 - Metabolites of (+)-(2s,3s)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine: Metabolites of (+)-(2S, 3S)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine, and use of same....

20050261341 - Novel processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol: The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:...

20050261340 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions....

20050261344 - Treatment of lower urinary tract symptoms associated with overactive bladder in men and women: This invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with either overactive bladder or mild to moderate benign prostatic hyperplasia, which combinations contain an alpha-adrenoceptor antagonist and a 5-HT4 antagonist. The combinations of the invention are particularly suitable for treating moderate or severe symptomatology....

20050261345 - 2,5-bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor: 2,5-bis-diamine-[1,4]benzoquinonic derivatives, having a general formula (I) have proved useful for the treatment of Alzheimer's disease; a method for preparing them and intermediates used in said method are also described....

20050261346 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders....

20050261347 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same: v

20050261348 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor....

20050261349 - Medicine for prevention or treatment of diabetes: The present invention provides a medicine for preventing or treating a diabetes, which includes 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, and glibenclamide as active ingredients. The present invention provides a method for preventing or treating a diabetes, which includes administering 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof,...

20050261350 - Pyrrolobenzimidazolones and their use as anti-proliferative agents: e

20050261352 - Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides:

20050261351 - Process for preparing ondansetron hydrochloride dihydrate having a defined particle size: The invention provides a process for preparing ondansetron hydrochloride dihydrate particles in which at least about 70% of the particles have a particle size of less than 250 μm, comprising the steps of: (a) preparing a solution comprising ondansetron hydrochloride and water; and (b) adding the solution into a precipitation...

20050261353 - Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents: that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of...

20050261354 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20050261355 - Carvedilol hydobromide: The present invention relates to a salt of carvedilol, corresponding compositions containing such a carvedilol salt or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to a novel crystalline form of...

20050261356 - Methods and compositions for the treatment of chronic lymphocytic leukemia: The level of the leukemic lymphocytes in patients suffering from chronic lymphocytic leukemia (CLL) is reduced by the administration of certain indole or carbazole compounds, such as the nonsteroidal anti-inflammatory drug etodolac or related indole or carbazol compounds....

20050261357 - Indole derivatives and drugs containing the same: e

20050261358 - Cyclohexylurea compounds:

20050261361 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261359 - Novel processes for preparing amorphous atorvastatin hemi-calcium: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261360 - Novel processes for preparing amorphous atorvastatin hemi-calcium: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261362 - Method of increasing endogenous adiponectin and leptin production: A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The...

20050261363 - Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same: Disclosed herein are an acetone-extracted product obtained from gamboge resin and compounds further purified from said acetone-extracted product, including a new compound called formoxanthone A. The acetone-extracted product and the further purified compounds have been demonstrated to have activities in inhibiting the growth of tumor/cancer cells. Also disclosed are the...

20050261364 - Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor: Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral...

20050261365 - Transthyretin stabilization: Dibenzofuran-4,6-dicarboxylic acid core structures having an aromatic substituent appended onto the at the C1 position using three different types of linkages are disclosed herein and shown to afford exceptional amyloidogenesis inhibitors that display increased affinity and greatly increased binding selectivity to TTR over all the other plasma proteins, relative to...

20050261367 - Methods for treating dermatological and other health-related conditions in a patient: A method is provided for treating a dermatological condition in a patient. The method includes (a) measuring the intracellular water content of the patient to provide an initial intracellular water content measurement; (b) administering to the patient at least one active agent; (c) re-measuring the intracellular water content of the...

20050261366 - Tri(alkylcarboxylato)gallium (iii) products and pharmaceutical compositions containing them: Provided are novel tri(alkylcarboxylato) gallium (III) compounds, exemplified by tripalmitato gallium (III), methods for making them, pharmaceutical compositions containing them, and methods of using the pharmaceutical compositions....

20050261368 - Preparation of levalbuterol hydrochloride: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided....

20050261369 - Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor: This invention describes a new combination for the treatment of bladder function disorders which comprises a serotonin- and/or norepinephrine-reuptake inhibitor and a beta-3-adrenoceptor agonist....

20050261370 - Process for producing of an aminoalkylsulfonic acid and a method of salt exchange for a salt thereof: i

20050261371 - Pentanoic acid derivatives: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or...

20050261372 - Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid: The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C1-C6)alkyl, (C3-C6)alkenyl, 3-oxo(C5-C6)alkyl, 3-oxo(C4-C6)alken-2-yl, phenyl(C1-C6)alkyl, phenyl(C2-C6)alkenyl, gem-diphenyl(C1-C6)alkyl, gem-diphenyl(C2-C6)alkenyl, (C1-C6)alcanoyl, optionally N-substituted alanyl, optionally N,N′-disubstituted lysinoyl, phenyl(C1-C6)alkylydene or gem-diphenyl(C1-C6)alkylidene group, and of the pharmaceutically acceptable salts thereof, for preparation of medicaments intended for the treatment of CNS diseases due to reduced...

20050261375 - Method for providing a cathartic effect: e

20050261374 - Process for the preparation of prostaglandins and analogues thereof: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2α....

20050261373 - Prostaglandin compounds for the treatment of obesity: Provided is a composition for treating obesity which comprises an effective amount of a prostaglandin compound, especially, a compound of formula (I)....

20050261376 - Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid: o

20050261377 - Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction: Methods for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity....

20050261378 - Process for decreasing adiposity using vitamin a as a dietary supplement: A process is provided for reducing adiposity in an animal such as a companion animal by feeding the animal an effective amount of Vitamin A for a time sufficient to reduce adiposity in the animal. Preferably, the such effective amount comprises from about 50,000 IU to about 1,000,000 IU of...

20050261379 - Spray oil and method of use therefor for controlling turfgrass pests: A paraffinic spray oil and a method of using the spray oil for controlling turfgrass pests is disclosed. The spray oil comprises paraffinic oil and a quick break emulsifier, which is formulated as an oil-in-water (O/W) emulsion for use. The paraffinic oil and emulsifier are present in a weight ratio...

20050256031 - Composition for relieving discomfort: The invention relates to a method of controlling feelings of pain in infants or diseased or elderly persons using a complete nutrition or a nutritional supplement. The method comprises administering increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents....

20050256030 - Heterocyclic self-immolative linkers and conjugates: The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that...

20050256029 - Methods and compositions for alleviating stuttering: Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class...

20050256033 - Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed...

20050256032 - Polyoxyalkylene compound and method for making: A process for forming a conjugate of a polyoxyalkylene polymer, such as polyethylene glycol, with a compound containing an amine group(s) and/or a sulfide group(s) by reacting the compound with an acrylate terminated polyoxyalkylene, such as polyethylene glycol terminated at one end with acrylate or methacrylate and terminated at the...

20050256028 - Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase: Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that...

20050256034 - Dioxolane analogs for improved inter-cellular delivery: t

20050256035 - Ctp-extended erythropoietin: Erythropoietin containing a CTP extension and secreted from CHO cells exhibits a favorably extended biological half-life....

20050256036 - Gastrointestinal proliferative factor and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa....

20050256037 - Antibacterial amide macrocyles: The invention relates to antibacterial amide macrocycles and process for their preparation, their use for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially of bacterial infections....

20050256045 - Apparatus and method for transdermal delivery of parathyroid hormone agents: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In...

20050256040 - Artificially designed pore-forming proteins with anti-tumor effects: Protein engineering is an emerging area that has expanded the understanding in the art of protein folding and laid the groundwork for the creation of unprecedented structures with unique functions. The first native-like pore-forming protein, small globular protein (SGP), has previously been designed. It has now been discovered that this...

20050256049 - Chimeric toxins for targeted therapy: The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist of Pseudomonas Exotoxin A. The...

20050256053 - Combined use of a glp-1 compound and another drug for treating dyslipidemia: Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug....

20050256046 - Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use: The present invention provides molecular weight markers for accurate determination of the molecular weight of glatiramer acetate and other copolymers. The present invention further provides a plurality of molecular weight markers for determining the molecular weight of glatiramer acetate and other copolymers which display linear relationships between molar ellipticity and...

20050256044 - Gastrointestinal proliferative factor and uses thereof: The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor (GIPF) polynucleotides and polypeptides. The invention further relates to the therapeutic use of GIPF to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa....

20050256043 - Hiv antisense proteins: Disclosed is a novel HIV gene comprising a set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat. The genes encode a set of antisense proteins, (HAPs) as well as smaller proteins, related...

20050256047 - Method for fostering bone formation and preservation: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any...

20050256052 - Method of modulating tissue growth using frzb protein: An isolated cDNA encoding a growth-inducing protein, Frzb, capable of stimulating bone, cartilage, muscle and nerve tissue formation. Frzb binds to and modulates the activity of Wnt growth factors which play a role in various developmental and neoplastic processes. The cDNA and protein sequences of human, bovine and Xenopus Frzb...

20050256042 - Methods of preventing and treating alimentary mucositis: The present invention relates to compositions and methods for preventing and treating alimentary mucositis. More particularly, the present invention provides methods for preventing and/or treating alimetary mucositis by using compositions comprising FGF-20, a fragment, a derivative, a variant, a homolog, or an analog thereof....

20050256039 - Novel fibroblast growth factors and methods of use thereof: The present invention relates to compositions and methods of treatment of various conditions, including but are not limited to, stroke, wound healing, and joint diseases (e.g., osteoarthritis and rheumatoid arthritis). More particularly, the present invention relates to compositions comprising a member of the fibroblast growth factor family, FGF-CX (also known...

20050256051 - Nuclear receptor-mediated introduction of a pna into cell nuclei: Disclosed are compositions and methods for introducing Peptide Nucleic Acids (PNAs) into cell nuclei. The PNAs are linked to a ligand that binds a nuclear receptor. The methods have therapeutic and diagnostic applications....

20050256048 - Selective androgen receptor modulators and methods for their identification, design and use: Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided....

20050256038 - Stable pharmaceutical compsition containing factor viii: The invention relates to a stable solid pharmaceutical composition comprising factor VIII. Such a composition is devoid of amino acids and comprises: (a) factor VIII; (b) a surfactant; (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate; and (g) a buffer devoid of amino acids; and has a...

20050256050 - Vascular endothelial growth factor 2: Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound healing...

20050256041 - Ztnfr14, a tumor necrosis factor receptor: Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and...

20050256055 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium....

20050256054 - Drug therapy for celiac sprue: Celiac Sprue and/or dermatitis herpetiformis arc treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i)...

20050256056 - Peptide inhibitors of hiv: Provided are peptides, peptide analogs, and peptide mimetics that inhibit HIV activity, pharmaceutical compositions comprising such peptides and peptide analogs, and methods of inhibiting HIV activity and/or transmission by administering the peptides and peptide analogs to a subject....

20050256058 - Propenoyl hydrazides: The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include a peptidyl propenoyl hydrazide compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro....

20050256057 - Protein hydrolysate rich in tripeptides: The present invention describes a protein hydrolysate which is rich in tripeptides whereby the tripeptides are rich in proline at one end of the peptide....

20050256059 - Methods and compositions for treatment of neurological disorder: The present invention provides methods and compositions for producing a neurosalutary effect in a subject useful in treatment of neurological disorders, including retinal and optic nerve damage, in a subject in need thereof. The method includes administering to a subject a therapeutically effective amount of a hexose, such as mannose....

20050256060 - Mono-and disaccharide derivatives: The present invention relates to a novel family of monosaccharide derivatives and disaccharide derivatives and to a method of preparation thereof. A mono- and disaccharide derivatives according to the invention comprises at least one fatty acid ester and may further comprise one or more anionic groups and are useful for...

20050256061 - Use of isoflavones for preparing topical compositions for promoting slimming, and related cosmetic treatment method: The invention concerns the use of isoflavones for ping topical compositions for promoting slimming, and in particular for fighting against localized excess weight; the related cosmetic treatment method and a composition comprising additionally to isoflavones an extract of Sophora Japonica flowers....

20050256062 - Crystal forms of azithromycin: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections....

20050256063 - Crystal forms of azithromycin: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections....

20050256064 - 9-desoxoerythromycin compounds as prokinetic agents: e

20050256065 - Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents: The present invention relates to methods and compositions for stabilizing a change in corneal curvature, stabilizing refractive error improvements and stabilizing (maintaining) unaided visual acuity improvements after corneal reshaping procedures. This stabilization process is accomplished by administering compositions containing at least one stabilizing ophthalmic agent to the cornea of the...

20050256066 - Fredericamycin derivatives: The invention relates to novel fredericamycin derivatives, to drugs containing said derivatives or the salts thereof, and to the use of the fredericamycin derivatives for treating diseases, especially cancer diseases....

20050256070 - Adjuvant: The present invention relates to the fields of vaccines, vaccine adjuvants, molecular biology and immunology, and generally adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies employing such compositions. The invention in particular relates to DNA...

20050256072 - Dual functional oligonucleotides for use in repressing mutant gene expression: The present invention is based, in part, on the discovery that endogenous mRNAs can be recruited for translational repression of target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means by which to treat genetic (e.g., genetic neurodegenerative diseases such as Huntington's Disease) or non-genetic diseases...

20050256077 - Gastrointestinal stem cells and uses thereof: The present invention relates to compositions and methods concerning isolated gastrointestinal stem cells. Particularly, the invention provides isolated gastrointestinal stem cells comprising a CD45 negative marker, a collagen IV negative marker, and that is Msi-1 positive. In particular embodiments the isolated cells are comprised in a single cell suspension. In...

20050256073 - Immunostimulatory viral rna oligonucleotides: Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3′ terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5′-C/U-U-G/U-U-3′. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new...

20050256071 - Inhibitor nucleic acids: The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an...

20050256069 - Irna agents with biocleavable tethers: The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group....

20050256067 - Method of preparing a treatment product, treatment product and a plasmid construct: The method of the invention for preparing a treatment product is characterized by using a starting plasmid based on a virus belonging to the Togaviridae stock from which the genes encoding capsid proteins of the virus have been deleted. An RNA encoding virus-like particles (VLP-RNA) is prepared by manipulating the...

20050256074 - Methods and compositions for regulating lymphocyte activity: The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention provides a method to promote T lymphocyte development using low dose Hedghog, and a method to inhibit T lumphocyte development using high dose...

20050256068 - Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene...

20050256076 - Rna interference modulators of hedgehog signaling and uses thereof: The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment...

20050256075 - Use of vegf-c or vegf-d gene or protein to prevent restenosis: The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins....

20050256078 - Inosine monophosphate dehydrogenase inhibitory phosphonate compounds: The invention is related to phosphorus substituted IMPDH inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20050256080 - Method for reducing malodor of chondroitin: The present invention relates to a method of removing or masking odor associated with chondroitin derived from marine life. The method comprises blending the chondroitin with citric acid, silicon dioxide, and optionally a flavorant to yield a substantially non-malodorous blend....

20050256079 - Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained: A new method is described for the oversulfation of (epi)KS-N sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new Nacyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical...

20050256081 - Tetracycline derivatives for the treatment of ocular pathologies: Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in...

20050256082 - Allergen inactivator: r

20050256083 - Preserved pharmaceutical compositions comprising cyclodextrins: A composition comprising a cyclodextrin, a guanidine-based cationic compound, and sorbic acid is disclosed herein. Preservatives and methods related thereto, and experimental results suggesting certain advantages related to these compositions, preservatives, and methods are also presented herein....

20050256084 - Antiallergic composition: The present invention provides a sate and excellent antiallergic composition, and more particularly a preventive and therapeutic composition for atopic dermatitis, including an antiallergic composition blended with stachyose as an effective ingredient, and a medicine, food and beverage containing the composition....

20050256085 - Fungicidal mixtures: e

20050256086 - Fosinopril formulation: A pharmaceutical formulation is provided comprising fosinopril which is the prodrug of an angiotensin converting enzyme (ACE) inhibitor, fosinoprilat. The formulation is characterized by comprising in the range of about 0.25 to about 5% glyceryl dibehenate which has been found to be a highly useful lubricant in the manufacture of...

20050256087 - Phosphonic acid diester compounds: p

20050256090 - Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes:

20050256088 - Pharmaceutical nitrones: Pharmaceutical nitrone comprise condensates of an N-hydroxylamine and a physiological aldehyde, providing improved delivery and absorption, enhanced stability and reduced toxicity. Preferred physiological aldehydes are subject to endogenous cellular uptake transport, and include pyridoxal, pyridoxal phosphate, and heme-A. Essentially any physiologically compatible and pharmaceutically active hydroxylamine moiety may be incorporated,...

20050256089 - Phenyl-substituted 4-hydroxy-tetrahydropyridones: a

20050256091 - Compositions based on cupric salts cupric salts and their use for controlling phytopathogens: Fungicidal compositions are described, containing one or more salts of derivatives of salicylic acid having formula (I): in any molar ratio, with at least one fungicidal compound not corresponding to a salt of derivatives of salicylic acid having formula (I)....

20050256092 - Antipsoriatic agent: n

20050256093 - Branched polyamine steroid derivatives:

20050256094 - Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein: Intermediates in the preparation of 9,11-epoxy steroids are disclosed. Particularly, disclosed are 11,12-epoxy steroid, 4,5-9,11-diepoxy steroid and 12-keto steroid intermediates....

20050256095 - Asthma and colitis treatment methods: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of...

20050256096 - C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert...

20050256097 - Pharmaceutical solution formulations containing 17-aag: A pharmaceutical solution formulation containing 17-AAG in an amount of up to 15 mg/mL dissolved in a vehicle comprising (i) a first component that is ethanol, in an amount of between about 40 and about 60 volume %; (ii) a second component that is a polyethoxylated castor oil, in an...

20050256098 - Cgrp receptor antagonists: (where variables R1, R2, R3, R4, A, B, G, J, Q, T, U, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache....

20050256099 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds,...

20050256100 - Protease inhibitors: e

20050256101 - Plant extracts and alkaloids having antitussive activity: The present invention provides plant extracts, isolated alkaloids, synthetic alkaloids and compositions having antitussive activity. In some preferred embodiments, the plant extracts and the isolated alkaloids are from a plant of a genus in the family Stemonaceae. In other preferred embodiments, the plant extracts and the isolated alkaloids are from...

20050256102 - Compounds and methods for inhibiting mitotic progression: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer....

20050256103 - Indole derivative having piperidine ring: i

20050256104 - Protease inhibitors: The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including...

20050256107 - New substituted thiophene carboxamides, process for their preparation and their use as medicaments: e

20050256106 - Novel compounds, their use and preparation:

20050256105 - Protease inhibitors:

20050256108 - Spiroazacyclic compounds as monoamine receptor modulators: The present invention relates to spiroazacyclic compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment...

20050256109 - Hiv integrase inhibitors: cyclic pyrimidinone compounds: The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating...

20050256110 - Cyanopyrroles: wherein, T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted...

20050256111 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein R1-R4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to...

20050256112 - Combination of atypical antipsychotics and 5ht-1b receptor antagonists: (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally...

20050256115 - Aerosol formulation for the inhalation of beta-agonists: i

20050256113 - Anti-cytokine heterocyclic compounds:

20050256114 - Novel long acting bronchodilators for the treatment of respiratory diseases:

20050256116 - Novel biaromatic compounds which activate ppary type receptors and cosmetic/pharmaceutical compositions comprised thereof:

20050256117 - Ophthalmic compositions for treating ocular hypertension: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect...

20050256118 - Bicyclic-substituted amines having cyclic-substituted monocyclic substituents: wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are...

20050256119 - C-substituted tricyclic isoxazoline derivatives and their use as anti-depressants: The invention concerns substituted tricyclic isoxazoline derivatives according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular tricyclic dihydrobenzopy-ranoisoxazoline, dihydroquinolinoisoxazoline, dihydronaphthalenoisoxazoline and dihydrobenzothiopyranoisoxazoline derivatives substituted on the phenylpart of the tricyclic moiety with at...

20050256120 - Heterocyclo-substituted imidazoles for the treatment of inflammation: A class of imidazolyl compounds is described for use in treating inflammation. Compounds of particular interest are defined by formula (V), wherein R3 is a radical selected from hydrido, alkyl, haloalkyl, aralkyl, heterocycloalkyl, heteroaralkyl, acyl, cyano, alkoxy, alkylthio, alkylthioalkyl, alkylsulfonyl, cycloalkylthio, cycloalkylthioalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, haloalkylsulfonyl, arylsulfonyl, halo, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl,...

20050256121 - Substituted 2,5-heterocyclic derivatives: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:...

20050256123 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are...

20050256122 - Substituted pyridazinones: Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed....

20050256124 - Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto: s

20050256125 - Pyrimidine derivatives for the treatment of abnormal cell growth: or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R1-R4 and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates a method of using such compounds in the treatment of...

20050256126 - N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones:

20050256127 - 2-(6-{2-[(2r)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2h-pyridazin-3-one salts and their preparation: The present invention relates to salts of 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one, processes for their preparation, pharmaceutical compositions comprising such compounds, method of using them, and a process for preparing the active agent....

20050256128 - Antimycobacterial pharmaceutical composition: e

20050256129 - Compounds with 5-ht1a activity useful for treating disorders of the outer retina: Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed....

20050256130 - Substituted piperazines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists....

20050256131 - Pharmaceutical active substance combination and the use thereof: The invention relates to the use of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (nefazodone) or a pharmaceutically compatible salt thereof for producing medicaments used in the treatment of Parkinson's disease....

20050256132 - Use of er selective nf-kb inhibitors for the treatment of sepsis: The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for...

20050256133 - Thio-substituted arylmethanesulfinyl derivatives: wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity...

20050256134 - Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders: The present invention relates to the use of creatine compounds including cyclocreatine and creatine phosphate for treating or preventing a metabolic disorder consisting of hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases in a patient experiencing said disorder. The creatine compounds which can be...

20050256135 - Tetrahydronaphthyridine derivatives: e

20050256136 - Gyrase inhibitors and uses thereof: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with...

20050256137 - Pyridone compounds as inhibitors of bacterial type iii protien secreation systems: In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial...

20050256138 - Fungicidal triazolopyrimidines, method for the production thereof, use thereof for controlling harmful fungi, and agents containing said fungicidal triazolopyrimidines: Disclosed are a method for producing fungicidal triazolopyrimidine compounds, agents containing said compounds, and the use thereof for controlling harmful fungi. Also disclosed are triazolopyrimidines of formula (1), in which the substituents have the following meaning: L1 represents alkyl; L2 represents halogen; L3represents hydrogen or halogen; X represents halogen, cyano,...

20050256139 - Amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same: The present invention relates to a new and useful amorphous form of ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride) and preparations thereof....

20050256140 - Condensed pyridines and pyrimidines with tie2 (tek) activity: A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the...

20050256141 - Remedies for glomerular diseases: The present invention relates to a preventive or therapeutic agent for a glomerular disease which comprises an anti-thrombocytic agent and an HMG-CoA reductase inhibitor as active ingredients. The above agent is useful for prevention and therapy of various glomerular diseases including chronic glomerular nephritis....

20050256142 - New purine derivatives: R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke,...

20050256143 - Purine nucleosides: Disclosed are purine nucleoside compounds that are selective to A3 adenosine receptors and are useful for the treatment of cancer and inflammatory diseases. The compounds are shown by the following general formula (I), including isomers thereof: wherein X is sulfur or oxygen; R1 is hydrogen, alkyl, benzyl, halobenzyl, or phenylalkyl;...

20050256144 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein A and Ar are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to...

20050256145 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions...

20050256146 - Alpha-7 nicotinic receptor agonists and stains in combination: Combinations of α7-nAChR agonists and statins, pharmaceutical compositions containing the same and methods of using the same useful for treatment or prophylaxis of neurological degenerative diseases....

20050256147 - Neuroprotective properties of dextrorotatory morphinans: The present application discloses a pharmaceutical composition for treating Parkinson's disease and psychotropic intoxication/abusive potential, which contains a morphinan compound....

20050256148 - Esters in position 20 of camptothecins: Formula (I) compounds are described: (I) where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable sales. Said compounds are topoisomerase I inhibitors....

20050256149 - Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts: Pharmaceutical compositions and kits comprising: (a) a tiotropium salt; and (b) a salmeterol salt having a solubility in water of 0.1 mg/mL or less, processes for preparing them, and their use in the treatment of respiratory complaints, asthma, and chronic obstructive pulmonary disease (COPD)....

20050256150 - Enantioselective acyl transfer catalysts and their use in kinetic resolution of alcohols and desymmetrization of meso-diols: a

20050256151 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune...

20050256154 - 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides: Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon,...

20050256152 - Salt of a sulfonic acid containing clopidogrel and use thereof for the production of pharmaceutical formulations: The present invention relates to the salt of a sulfonic acid with clopidogrel and pharmaceutical formulations comprising this salt....

20050256153 - Thienopyridinone compounds and methods of treatment: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux...

20050256155 - Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics: Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder. The present invention further provides the use of a compound of formula (I) for the...

20050256156 - Processes for preparing montelukast sodium: The present invention provides processes for preparing montelukast....

20050256157 - Combination therapy with chk1 inhibitors: Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be...

20050256158 - Pgd2 receptor antagonists for the treatment of inflammatory diseases: m

20050256159 - 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors: A method for inhibiting 11βHSD1 by administering a compound of formula (I) is described, wherein A, X, Y, R1, R12, n, q, and m are as described in the specification. Novel compounds and methods employing them are also described and claimed....

20050256160 - Beta-alanine derivatives and the use thereof: (wherein the symbols are as defined in the description), or a prodrug or a salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be...

20050256163 - Crystalline forms of fexofenadine hydrochloride and processes for their preparation: Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation....

20050256162 - Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles: o

20050256161 - Melanin concentrating hormone receptor antagonists:

20050256164 - Nk1 and nk3 antagonists: The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions....

20050256165 - Doxepin analogs and methods of use thereof: The invention relates to novel doxepin analog compounds and methods of modulating sleep by administering such compounds, or a pharmaceutically effective salt thereof....

20050256166 - Nitrogen-containing compounds: wherein ring A represents a nitrogen containing heterocyclic ring, ring B represents 5-membered heterocyclic ring which may have substituents, R represents a hydrogen atom or cyano and the other symbols represent as described in the specification; or a salt thereof. The compound represented by formula (I) has an inhibitory activity...

20050256167 - Preparation and use of imidazole derivatives for treatment of obesity: This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders....

20050256168 - Compositions for oral administration for the treatment of interferon-responsive disorders: Compositions and methods of treatment of interferon-responsive disorders are provided wherein the methods, for example, comprise orally administering a composition which comprises a therapeutically effective amount of at least one alkylated imino sugar having an alkylated side chain, and a pharmaceutically acceptable carrier....

20050256170 - Ep2 receptor agonists: m

20050256169 - Nitric oxide scavengers: Therapeutic compositions capable of removing excess nitric oxide are provided. The therapeutic compositions include nitronyl nitroxide monoradicals, B12 derivatives, flavonoid derivatives, the like and combinations thereof. The therapeutic compositions can be utilized in a number of suitable applications, such as to prevent or treat intradialytic hypotension during dialysis....

20050256171 - Pyrrolidine derivatives as tryptase inhibitors: e

20050256172 - Novel derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing them: are described wherein n is an integer from 1 to 4, R1 is a hydrogen atom, hydroxyl group or lower C1-6alkoxy group R2 is a hydrogen atom or a straight or branched lower C1-6alkyl group X, is hydrogen, fluorine, chlorine, bromine, hydroxyl group, trifluoromethyl group, 3,4-di-Cl,2,4-di-Cl or lower C1-6alkoxy group,...

20050256173 - Heterocyclic fluoroalkenyl thioethers and the use thereof as pesticides (i): e

20050256174 - Raf kinase inhibitors: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se....

20050256175 - Novel glucagon antagonists/inverse agonists: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists....

20050256176 - Sulphonamide derivatives and their use as tace inhibitors: Sulphonamide derivatives that are useful in the inhibition of metalloproteinases and in particular in the inhibition of TNF-α Converting Enzyme (TACE)....

20050256177 - Phenyl derivatives for the treatment of abnormal cell growth: wherein X1, X2 and X3 independently is a halogen; p is an integer from 1 to 3; and R is —COOH, OR1 wherein R1 is a substituted isothiazole ring, or SR2 wherein R2 is (CH2)qC(COOH)(NHC(O)R3) wherein q is an integer from 0 to 3, and R3 is (C1-C4)alkyl; and to...

20050256178 - Novel nutraceutical compositions comprising boitin: Nutraceutical compositions comprise biotin in an amount sufficient to administer to a subject a daily dosage of 0.01 mg per kg body weight to about 3 mg per kg body weight and at least one additional component selected from pantethine or a metabolite thereof, EGCG, phytanic acid, lipoic acid and...

20050256179 - Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases: Preferred aspects of the present invention relate to the inhibition of intracellular protein trafficking pathways through selective pharmacologic down-regulation of specific resident ER and golgi proteins, and more particularly, to methods of treating a variety of disease conditions, which depend on these intracellular protein trafficking pathways....

20050256180 - Substituted pyrazolyl compounds for the treatment of inflammation: The present invention relates to substituted pyrazolyl derivatives, compositions comprising such, intermediates, methods of making substituted pyrazolyl derivatives, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis....

20050256181 - Treating a viral disorder: Heterocyclic compounds of formula (I) and methods of treating or preventing an HIV-mediated disorder by administering a compound of formula (I) are described herein....

20050256182 - Formulations of anti-pain agents and methods of using the same: The present invention relates to novel anti-pain formulations and methods of their delivery. Anti-pain agents delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods, including oral, intramuscular and subcutaneous delivery. The methods of the present invention...

20050256183 - Hsp90-inhibiting zearalanol compounds and methods of producing and using same: Zearalanol compounds are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various disorders. Methods of synthesis and use of such compounds are also described and claimed....

20050256184 - 1,2,4-trioxanes and 1,2,4-trioxepanes: Novel substituted 1,2,4-trioxanes and 1,2,4-trioxepanes useful as anti-malarial and/or anticancer agents, and an improved method for their preparation, preferably involving a thiol-olefin co-oxygenation (TOCO) reaction between an allylic alcohol and a ketone....

20050256185 - Spiro and dispiro 1,2,4-trioxolane antimalarials: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted...

20050256186 - Prevention of and countermeasures against mitochondrial disease: The present invention relates to an agent containing L-arginine, 0.2 to 20 parts by weight of L-ascorbic acid per 1 part by weight of L-arginine, and, if desired, at least one selected from the group consisting of ribonucleic acids, ribonucleotides and ribonucleosides. The agent can treat mitochondrial disease which shows...

20050256187 - Method and composition for synergistic topical therapy for neuromuscular pains: The invention relates to a method and composition for synergistic topical therapy of the symptoms of neuromuscular pains. In this method, for intact skin or open skin, there is used a suitable topical pharmaceutical formulation, which is loaded in a suitable dose relationship with a sodium channel blocker from the...

20050256188 - Formulations of anthraquinone derivatives: A compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R′R″ of at least 2 carbon atoms and R′ and R″ are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 dihydroxyalkyl groups, or R′ and R″...

20050256189 - Method of treating dry eye disorders and uveitis: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis....

20050256190 - Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium: Disclosed are a method for activating lipid metabolism in the small intestine epithelium and also a method for promoting accumulation of fatty acids into the small intestine epithelium, each of which features administering an effective amount of a diacylglycerol. Also disclosed are methods for improving various symptoms in diabetes, which...

20050256193 - Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity: The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity....

20050256194 - Denaturants for sympathomimetic amine salts: The instant invention makes impractical the use of sympathomimetic amine compositions in illicit drug production. More specifically, the preparation of methamphetamine from the disclosed pseudoephedrine hydrochloride formulations is inhibited. The present invention defines pharmaceutical compositions comprising a sympathomimetic amine salt and at least one combination inhibitor, the combination inhibitor which...

20050256191 - Nitroaniline-based alkylating agents and their use as prodrugs: Nitroaniline-based unsymmetrical mustards of the general formula (I) are provided, together with methods of preparation and methods for their use as prodrugs for gene-dependent enzyme prodrug therapy (GDEPT) and cell ablation therapy in conjunction with nitroreductase enzymes as hypoxia selective cytotoxins and as anticancer agents....

20050256192 - Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increas: A nutritional composition, the consumption of which provides a method for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in individuals. The nutritional...

20050256195 - Composition for preventing hypertension: This invention relates to a composition that can inhibit the elevation of blood pressure, does not generate any side effects, and can be safely used. Particularly, this invention relates to food or a pharmaceutical composition for preventing hypertension that can inhibit the elevation of blood pressure via the long-term oral...

20050256196 - Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids: The present invention relates to the treatment or prevention of glutamatergic toxicity by the administration of effective amounts of branched chain α-keto acids alone or in combination with other antiglutamate agents such as L-methionine S-sulfoximine, L-ethionine S-sulfoximine, and glufosinate. In particular, the present invention relates to the treatment or prevention...

20050256197 - Methods and compositions for facilitating metabolic control: The present invention provides methods for facilitating metabolic control in a subject by decreasing the level of Il-1β in the GCF. The present invention further provides methods for decreasing the level of circulating TNF in a subject. Also provided are uses of anti-inflammatory agents in these methods....

20050256198 - Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance: The present invention provides a compound of formula (I), wherein n is 0, 1 or 2 and R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2...

20050256199 - 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors: The present invention relates to 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors....

20050256200 - Benzoyl peroxide compositions having increased potency: A benzoyl peroxide composition having increased potency includes benzoyl peroxide, a tertiary amine and/or a transition metal, and a base that increases radicals formed by the peroxide....

20050256201 - Phenethanolamine derivatives: b

20050256202 - Process for preparing atazanavir bisulfate and novel forms: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are...

20050256203 - Carboxamido opioid compounds: This invention is directed to carboxamido opioid compounds pharmaceutically useful as agents for treating or modulating a central nervous system disorder and methods for treating or modulating a central nervous system disorder....

20050256204 - Topical phenyl-epinephrine rosacea treatment: A near-permanent skin treatment includes photothermolysis of reddened facial skin to induce ischemia. Reperfusion of the photothermolysis treated skin is inhibited by following with regular applications of phenyl-epinephrine carried in a lotion until vascular necrosis is complete. Alternatively, a temporary treatment for reddened facial skin includes only cosmetic as-needed applications...

20050256205 - Crystalline forms of venlafaxine hydrochloride: Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms....

20050256206 - Enantiomers of o-desmethyl venlafaxine: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central...

20050256207 - Methods for modulating macrophage proliferation in ocular disease using polyamine analogs: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also...

20050256208 - Pharmaceutical composition containing bakuchiol for treating woman breast cancer: The present invention discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering breast cancer. An embodiment of this novel use is a pharmaceutical composition containing bakuchiol or an extract containing bakuchiol, which can be in the dosage forms of topical use,...

20050256209 - Pharmaceutical composition containing bakuchiol for treating woman osteoporosis: The present invention discloses a novel use of bakuchiol or an extract containing bakuchiol in preventing or treating a woman suffering osteoporosis. An embodiment of this novel use is a pharmaceutical composition containing bakuchiol or an extract containing bakuchiol, which can be in the dosage forms of topical use, oral...

20050256210 - Compounds with activity at estrogen receptors: Disclosed herein are novel di-phenyl compounds and methods for using various di-phenyl compounds for treatment and prevention of diseases and disorders related to estrogen receptors....

20050250671 - Activators of peroxisome proliferator-activated receptor: Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient....

20050250672 - Preparation for the prophylaxis of restenosis: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one...

20050250675 - Antitumor agents: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising...

20050250673 - Neurodegenerative disease treatment: A method of identifying a 5′AMP-activated protein kinase inhibitor for treating a neurodegenerative disease. Disclosed are a method and a packaged product for treating a neurodegenerative disease. Also disclosed is a method for treating a 5′AMP-activated protein kinase-related disease and a related packaged product....

20050250674 - Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs: The present invention provides nutritional, pharmaceutical, or dietetic preparations that comprise creatine and orotic acid derivatives, creatine-orotic acid complexes and derivatives thereof, and functional analogs of such compounds and compositions, and the use of these compounds and compositions in the treatment of enhanced body performance of humans and animals, or...

20050250676 - Method of activating insulin receptor substrate-2 to stimulate insulin production: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate...

20050250679 - Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use: A conjugate of formula A-L-P, in which: A represents a glycosylated/galactosylated peptide that binds to a cell-surface receptor, L represents a bifunctional linker, which does not comprise a naturally occurring amino acid and is covalently bonded to A and P in a regiospecific manner, and P represents a monomer, homopolymer...

20050250677 - Glycopeptide antibiotic derivatives: Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives...

20050250678 - O-linked glycosylation of peptides: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue...

20050250680 - Stabilized alpha helical peptides and uses thereof: Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive...

20050250682 - Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions: Compositions useful for treating membrane-associated diseases, conditions, and disorders, including inflammatory diseases, dry mouth, primary ciliary dyskinesia and platelet aggregating disorders, are disclosed which comprise at least one lantibiotic compound. Also disclosed are pharmaceutical compositions and methods of treatment for membrane-associated diseases such as inflammation and dermal irritation, as well...

20050250681 - Treatment of ocular diseases and disorders using lantibiotic compositions: Compositions and methods for treating ocular diseases and disorders are provided. The composition can contain at least one lantibiotic, which can be administered topically by injection, systemically, or by other appropriate means. The methods provided include the administration of a therapeutically effective amount of a formulation containing at least one...

20050250686 - Angiogenesis using hepatocyte growth factor: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided....

20050250689 - Antagonists for human prolactin: A modified human prolactin molecule wherein the prolactin molecule comprises at least one mutation in a region selected from i) amino acids 41-57, ii) amino acids 94-110, and iii) amino acids 160-173; and wherein the at least one mutation is selected from deletions, replacements, and insertions. The modified prolactins are...

20050250687 - Anti-tumor activity of ea-4-peptide of pro-igf-i: Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization....

20050250695 - Combination pdgf, kgf, igf, and igfbp for wound healing: The invention provides a therapeutic composition for epithelial wound repair that is a combination of PDGF and KGF. Further, the invention provides a composition for epithelial wound repair that is a therapeutic combination of PDGF, KGF, and IGF. Additionally, the invention provides a therapeutic composition of PDGF, KGF, IGF and...

20050250692 - Compositions and methods for inhibiting cell proliferation: Disclosed are compositions and methods useful in the regulation of cell proliferation. The invention provides TGF-β (transforming growth factor β) and IGFBP-3 (insulin like growth factor binding protein 3) as ligands that engage LRP (low density lipoprotein receptor-related protein), heretofore known as TβR-V (TGF-β receptor V) and IGFBP-3 receptor, to...

20050250694 - Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same: The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein...

20050250691 - Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant....

20050250690 - Leptin peptide antagonists: Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling...

20050250693 - Metalloproteinase inhibitors: The present invention provides inhibitors of metalloprotineases that may be extracted from lactational secretions such as milk and colostrum. The inhibitors have use in the treatment of a range of diseases such as disorders of the gastrointestinal tract, cardiovascular conditions and wound healing. Methods for purifiying the inhibitors are also...

20050250697 - Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications: The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and/or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration...

20050250698 - Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications: The invention concerns a method for obtaining a highly enriched TGF-beta protein fraction in activated form, from a liquid solution rich in proteins said to be soluble in the aqueous phase of milk and/or of whey, said method comprising the following steps; a) adjusting soluble proteins purified at a concentration...

20050250684 - Method for reducing morbidity and mortality in critically ill patients: This invention relates to a novel method of reducing the mortality and morbidity in critically ill patients which comprises administering to the patients an effective amount of FGF-19....

20050250688 - Methods for treating an ischemic disorder and improving stroke outcome: The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable Factor IXa compound in a sufficient amount over a sufficient time period so as to treat the ischemic disorder in the subject. The invention further provides...

20050250685 - Peptides with wound healing activity: A number of peptides of from 28 to 44 amino acids, including therein a sequence of L-K-E-K-K (SEQ ID NO: 1) have a physiological activity that can be wound healing activity, immunostimulant activity, or growth factor activity. The peptides can be linear or circular, and if linear, the amino terminus...

20050250683 - Reversible modification of membrane interaction: An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized...

20050250696 - Truncated soluble tumor necrosis factor type-i and type-ii receptors: Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques....

20050250699 - Antimicrobial polypeptides: The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides....

20050250700 - Kdr and vegf/kdr binding peptides: The present invention provides, inter alia, peptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR...

20050250701 - Method of treating the syndrome of coronary heart disease risk factors in humans: The invention provides an improved method of treating a human suffering from one or more conditions included within the Coronary Heart Disease Risk Factor (CHDRF) syndrome. The method includes administering, by a pharmaceutically effective mode, a drug composition having an opioidergic agent including an opiate antagonist, opiate having μ-agonist activity...

20050250703 - Antioxidant constituents: An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite...

20050250702 - Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments: The invention relates to the field of proteins, more specifically to those proteins that are located on the surface of the cell. The invention, among other things, provides an inhibitor or pharmaceutical composition capable of inhibiting down-regulation of a cell surface receptor. The invention provides a method to control or...

20050250704 - Powder comprising new compositions of oligosaccharides and methods for their preparation: The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient....

20050250705 - Spray-dried powder comprising at least one 1,4 o-linked saccharose-derivative and methods for their preparation: The present invention relates to a spray-dried powder and method for its manufacture. A spray dried powder containing a pharmaceutical active substance and one or more 1,4 O-linked saccharose derivatives chosen from the compounds: 1,4 O-linked D-gal-saccharose (lactosucrose), 1,4 O-linked D-glu-saccharose (glucosyl sucrose) or 1,4 O-linked glu-glu-saccharose (maltosyl sucrose). Preferred...

20050250707 - Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing...

20050250706 - Processes for the preparation of alpha polymorph of perindopril erbumine: Processes for the preparation of an alpha polymorph of perindopril erbumine is provided comprising (a) forming a solution comprising perindopril erbumine in one or more ketones; (b) heating the solution to reflux; and (c) cooling the solution to a temperature sufficient to form the alpha polymorph of perindopril erbumine. The...

20050250708 - Novel c-glycosides, uses thereof: The present invention relates to novel C-glycoside compounds of given absolute configuration, to a process for synthesising them and to compositions containing them. The invention also relates to the cosmetic use of these C-glycoside compounds as agents to stimulate the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously...

20050250709 - Anti-neoplastic agents, combination therapies and related methods: In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems...

20050250710 - Antiaging composition: The present invention provides an antiaging composition capable of efficiently retarding skin-aging, particularly, alleviating skin pigmentation. The present invention also provides a method for potentiating the antiaging action of ascorbic acids. The invention provides an antiaging composition containing at least one member selected from the group consisting of ascorbic acid,...

20050250712 - Single dose azithromycin: The present invention relates to a method of treating infections in humans by administering a single dose of azithromycin....

20050250711 - Use of macrolides in pest control: There is now described a method of controlling pests with macrolide compounds; more specifically A) a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with a macrolide compound, characterized...

20050250713 - 11,12-cyclic thiocarbamate macrolide antibacterial agents: The present invention is directed to novel macrolide antibacterial agents and processes for preparing them. The present invention is further directed to pharmaceutical compositions containing the novel macrolide antibacterial agents disclosed herein and their use in the treatment and prevention of bacterial infections....

20050250714 - Crystalline forms of 9-(s)-erythromycylamine: The present invention provides novel crystalline forms of the macrolide antibiotic 9-(S)-erythromycylamine, and methods of preparing and using the same....

20050250715 - Remedy: The present invention relates to a therapeutic agent or prophylactic agent for a disease requiring enhancement of nerve growth factor (NGF) production upon treatment or prevention, an enhancing agent for nerve growth factor production, and a food, beverage or feed for enhancing nerve growth factor production, characterized in that each...

20050250717 - Chromatin remodeling protein as a marker expressed by stromal progenitor cells: The present invention provides a chromatin remodeling protein, designated ChroM as well as alternatively spliced variants, which serves as markers for stromal precursor cells and osteogenic and muscle progenitor cells. This ChroM marker was found to be present in proliferating progenitor cells but is either absent or not predominantly present...

20050250722 - Fcgammariia-specific nucleic acid interference: The present invention provides methods and compositions for attenuating expression of FcγRIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence....

20050250721 - Gene therapy for congestive heart failure: The present invention relates to methods and compositions for enhancing cardiac function in mammalian hearts by inserting transgenes that increase beta-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure....

20050250723 - Immunostimulation by chemically modified rna: The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed...

20050250726 - Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases: The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory...

20050250716 - Immunostimulatory oligodeoxynucleotides: The invention relates to the use of inununostimulatory deoxyinosine/deoxyuridine containing oligodeoxynucleotides for pharmaceutical application, such as treating and preventing chronic infectious diseases, acute decrements in air flow, parasitic infections and the like....

20050250719 - Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases: The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-α), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy....

20050250724 - Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death: Provided herein are methods relating to inhibition of PUMA function for preventing or reducing myocardial cell death. A method for preventing or reducing ischemia/reperfusion induced myocardial cell death in a human is provided as are methods for identifying pharmaceuticals which interfere with PUMA function. Also herein provided is a method...

20050250720 - Novel compound: A method for the provision of an appetite control agent which method comprises using one or more agonists or antagonists of a GPR19 receptor as test compounds in one or more appetite control test procedures, and selecting an active compound for use as an appetite control agent....

20050250718 - Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity: The present invention provides pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity. By attaching a compound to a minus-strand RNA virus envelope protein having hemagglutinating activity, a pharmaceutical- or gene-carrier composition with lower hemagglutinating activity than a composition to which the compound has not been attached can be successfully constructed....

20050250725 - Regulation of the p21 gene and uses thereof: The present invention in general is directed to methods for manipulating cyclin-dependent kinase inhibitor activity. Such manipulation will reduce or eliminate the expression of p21 gene based on specific requirements. This will be helpful in treating or preventing pathophysiological state in an individual which is characterized by undesirable level of...

20050250727 - Use of immunomodulating agents: Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described....

20050250728 - Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof: The efficacy of reverse transcriptase and DNA polymerase inhibitors (nucleoside analogs) in a mammalian host is enhanced by administering an effective amount of PNP inhibitor of prodrug of PNP inhibitor and/or an effective amounts of 2′-de-oxyguanosine and/or prodrugs thereof....

20050250729 - Novel adenosine a3 receptor agonists: wherein Ar, R and R1 have the meanings given in the specification. This series of sulfonamido derivatives with a conserved uronamide group at the 5′ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido derivatives N-substituted with aliphatic groups (cyclic or linear) or...

20050250730 - Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases: A combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) an adenosine A2A receptor agonist; and (ii) an anti-cholinergic agent, preferably comprising a member selected from the group consisting of tiotropium and derivatives thereof; the combination being therapeutically effective in the treatment...

20050250732 - Purified, moderately esterified polyol polyester fatty acid compositions: Processes for the production of purified, moderately esterified polyol fatty acid polyesters and the compositions derived from those processes. The purified, moderately esterified polyol fatty acid polyesters are particularly well suited for use in a variety of cosmetic, laundry, and industrial lubrication applications. The purified, moderately esterified polyol fatty acid...

20050250733 - Purified, moderately esterified polyol polyester fatty acid compositions: Processes for the production of purified, moderately esterified polyol fatty acid polyesters and the compositions derived from those processes. The purified, moderately esterified polyol fatty acid polyesters are particularly well suited for use in a variety of food, beverage, pharmaceutical, and cosmetic applications. Purified, moderately esterified polyol fatty acid polyester...

20050250731 - Synthesis of purified, moderately esterified polyol polyester fatty acid compositions: Processes for the preparation of a purified moderately esterified polyol fatty acid polyester composition including the steps of: forming an initial reaction mixture containing a polyol portion, a highly esterified polyol fatty acid polyester, a moderately esterified polyol fatty acid polyester; and a catalyst; wherein the molar ratio of the...

20050250734 - Compositions, kits, and methods for the treatment of conditions associated with elevated cholesterol levels: Disclosed herein are methods of treating a condition associated with elevated cholesterol levels are provided, comprising administering to a mammal in need of such treatment a safe and effective amount of a cholesterol biosynthesis inhibitor and a soluble fiber. Further disclosed herein are kits comprising a first composition comprising a...

20050250735 - Modified pectins, compositions and methods related thereto: The present invention provides compositions of modified pectin and for preparing and using them....

20050250736 - Composition and method for treatment of obesity and smoking cessation: The invention involves an instrument of weight loss by means of appetite suppression, along with a method for administering this preparation to humans and other mammals. The preparation consists of a variety of different spices, sweeteners, and salts, as well as proteins and alcohols. Additionally, there is a remedy for...

20050250738 - Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin: The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFT™...

20050250737 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in...

20050250739 - Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use: R6 and R6′ are selected from the group consisting of hydrogen, hydroxyl, alkoxyl, carboxyl, alkoxylcarbonyl, aminocarbonyl, alkylamino-carbonyl and dialylamino-carbonyl, with the proviso that Ring 1 is capable of binding to any of: a dopaminergic receptor selected from the group consisting of a D1 receptor and a D5 receptor; a DAT...

20050250740 - Novel indole derivatives as selective androgen receptor modulator (sarms): The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor....

20050250741 - Novel indole derivatives as selective androgen receptor modulators (sarms): The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor....

20050250742 - Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting nima (pin1): Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell...

20050250743 - Ammonium salts of inositol hexaphosphate, and uses thereof: The present invention comprises compounds, compositions thereof, and methods capable of delivering inositol hexaphospahte (IHP) to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to...

20050250744 - Pharmaceutically active compounds and methods of use thereof: The invention includes new substituted tetracycline-type compounds that exhibit significant antibacterial activity, including against both gram-positive and gram-negative bacteria. It has been found that compounds of the invention are highly active against both gram positive and gram negative tetracycline sensitive and tetracycline resistant bacteria....

20050250745 - Biomarkers for age-related macular degeneration (amd): Provided are methods of using levels of markers of systemic inflammation, e.g., CRP, to predict a subject's risk of development or progression of Age-Related Macular Degeneration (AMD), and methods of treating, delaying or preventing the development or progression of AMD....

20050250747 - Management of breakthrough bleeding in extended hormonal contraceptive regimens: The present invention relates to a flexible extended use regimen for a hormonal contraceptive useful to manage bleeding problems associated with fixed extended use of hormonal contraceptives and to a pharmaceutical package containing the respective hormonal contraceptive....

20050250746 - Premenstrual dysphoric disorder medication: A medication to treat the symptoms of premenstrual syndrome and similar conditions related to the periodic change in the physiological level of hormones in a woman's body....

20050250748 - Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease: Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat...

20050250749 - Helix 12 directed pharmaceutical products: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some...

20050250750 - Methods for treating postmenopausal women using ultra-low doses of estrogen: The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present...

20050250751 - Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents: e

20050250752 - Cembranoids with chemopreventive activity: A cembranoid compound of the following formula (I) as described herein. The compounds of the present invention are useful as chemopreventive and chemotherapeutic agents....

20050250753 - Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3: Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds....

20050250754 - Method of forming iron hydroxypyrone compounds: A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7....

20050250755 - Use of targeted oxidative therapeutic formulation in bone regeneration: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an...

20050250756 - Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an...

20050250757 - Use of targeted oxidative therapeutic formulation in treatment of cancer: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an...

20050250758 - Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use: The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis...

20050250759 - Spirolactams and their synthesis: New spirolactams having a benzodienone moiety and a azetidinone moiety which are highly stable due to pi interactions. They are useful as UV absorbers and as synthetic intermediates....

20050250760 - 1-[(indol-3-yl)carbonyl]piperazine derivatives: w

20050250761 - 4-phenylamino-quinazolin-6-yl-amides: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n—-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each...

20050250762 - Crystalline polymorph of bazedoxifene acetate: The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof....

20050250763 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these...

20050250765 - Diazepinones as antiviral agents: e

20050250764 - Soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors: The present invention describes a soluble stable pharmaceutical composition for the administration of HIV protease inhibitors. More specifically the composition comprises a solution of an HIV protease inhibitor in a combination of suitable pharmaceutical organic solvents, a surfactant and a bioavailability enhancer. It is also described a process for the...

20050250766 - Purification of progesterone receptor modulators: e

20050250767 - Use of n-desmethylclozapine to treat human neuropsychiatric disease: Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease....

20050250768 - Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal....

20050250769 - Heterocyclic cannabinoid receptor antagonists: e

20050250770 - Fused heterocyclic compounds: This invention provides fused heterocyclic compounds, pharmaceutical compositions of, the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders....

20050250772 - Methods for inducing anti-anxiety and calming effects in animals and humans: Phenolic compounds with a phenolic molecule to which are covalently linked an oxygen-containing group, a nitrogen or another oxygen containing group, and a C1-C4 alkoxy group, or their precursor compounds, obtainable from monocotyledonous plants, or by chemical synthesis, have been found to calm and/or reduce anxiety and related behaviors and...

20050250771 - Substituted indoles and their use as integrin antagonists: e

20050250773 - Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid: Provided are processes for the preparation of mycophenolate mofetil and other esters of mycophenolic acid....

20050250776 - Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1: o

20050250775 - Novel compounds: wherein R1, R2, R3, and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of...

20050250774 - Pyridine compounds: e

20050250777 - Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications:

20050250778 - Topical brimonidine tartrate formulations that lack chlorine dioxide: Topical solution compositions of brimonidine tartrate are disclosed. The solution compositions lack an oxidative preservative....

20050250779 - Pteridinone derivatives for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which lead to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective...

20050250780 - Reverse-turn mimetics and compositions and methods relating thereto: including pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3 and R4 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are neurokinin (tachykinin) antagonists....

20050250781 - Heterarylpiperidine modulators of chemokine receptor activity: The present invention is directed to compounds of the formula (I): (wherein R1, R2, R3, R4, R5, R6, R10 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2....

20050250782 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specifications. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are...

20050250783 - Fused heterocyclic compounds: d

20050250784 - Inhibitors of histone deacetylase: Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC....

20050250785 - Pna monomer and precursor: wherein E is nitrogen or C—R′; J is sulfur or oxygen; R′, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and B is...

20050250786 - Pna monomer and precursor: wherein E is nitrogen or C—R′; J is sulfur or oxygen; R′, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrite, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and B is...

20050250787 - Pyrimidine compounds: in which one of Ra and Rb is H or alkyl, and the other is aryl or heteroaryl optionally substituted with Rd and Rem; each of R2 and R4 is H; R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl; R5 is H or alkyl; n is 0, 1,...

20050250788 - Aqueous outflow enhancement with vasodilated aqueous cavity: A method for enhancing aqueous outflow and thereby lowering intraocular pressure is disclosed. The method comprises vasodilating aqueous veins by dilating or relaxing the smooth muscle of an aqueous cavity. In one embodiment, the step of dilating or relaxing the smooth muscle of the aqueous cavity is accomplished by slowly...

20050250789 - Hydroxamic acid derivatives as metalloprotease inhibitors: salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for example, arthritis, cancer, cardiovascular disorders, skin disorders, inflammation or allergic...

20050250790 - Novel sulfonic acid derivatives: l

20050250791 - Process for preparing monoarylpiperazines: The invention provides a process for preparing arylpiperazines from the corresponding aryl chlorides or bromides and piperazine using a base and a catalyst consisting of a palladium salt and a bisaryldialkylphosphine....

20050250792 - Substituted piperidine compounds useful as modulators of chemokine receptor activity: e

20050250794 - Methods of treating a disorder: Heterocyclic compounds of formula (I), (II), (III), and (IV) and methods of treating disorders by administering a compound of formula (I) (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders....

20050250793 - Preventives/remedies for hot flash: It is intended to provide a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, in particular, a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, wherein said compound is capable...

20050250795 - Synthesis of acyclic nucleoside derivatives:

20050250796 - Heterocyclic compounds:

20050250797 - Quinzoline derivatives for use in the treatment of cancer: The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive...

20050250798 - Pyrimidoindolones and methods for using same: Novel pyrimidoindolone compounds are disclosed. Methods of using the pyrimidoindolone compounds and compositions containing the compounds in the treatment and/or prevention of disease and other conditions related to inflammation, neurodegeneration, osteoarthritis and apoptosis are also disclosed....

20050250799 - Protease inhibitors for treatment of wrinkles: Methods, compositions, and kits are provided for the use of protease inhibitors, such as Ucf-101, to reduce wrinkles or other skin damage....

20050250800 - Conformationally constrained compounds as pharmaceutical agents: t

20050250801 - Method of treating cancer with azaspirane compositions:

20050250802 - Novel substituted amines of spirofuropyridines useful in therapy:

20050250803 - Combination of dopamine agonists and monoamine reuptake inhibitors: This invention is directed to pharmaceutical compositions and kits comprising (i) a dopamine agonist of the formula II as described in the specification, (ii) a monoamine reuptake inhibitor or pharmaceutically acceptable salt thereof; and optionally (iii) a pharmaceutically acceptable carrier. This invention further relates to methods of treatment using those...

20050250804 - Pharmaceutical gel formulations: A pharmaceutical gel composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) one or more gel forming agents; and (c) an effective amount of one or more skin...

20050250805 - Pharmaceutical ointment formulations: A pharmaceutical ointment composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) an ointment base; and (c) an effective amount of one or more skin penetration enhancers capable...

20050250806 - Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome: This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a...

20050250807 - Neurotrophin antagonist compositions: i

20050250808 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act...

20050250809 - Dichlorinated heterocyclic compounds and methods of synthesis: Compositions of the present invention comprise dichlorinated heterocyclic compounds, including dichloroflosequinan. The methods of the present invention also comprise the synthesis of dichloroflosequinan....

20050250810 - Fab i inhibitors: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections....

20050250812 - Methods for treating lewy body dementia: The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome,...

20050250811 - Pleuromutilin derivatives as antimicrobbials: e

20050250813 - Injectable depot formulation comprising crystals of iloperidone: An injectable depot formulation comprising crystals having Structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolite have the following advantages: (i) release of the crystals in plasma can be correlated with...

20050250814 - Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2....

20050250815 - Inhibitors of fractor xa and other serine proteases involved in the coagulation cascade: wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates...

20050250816 - Positive allosteric modulators of the nicotinic acetylcholine receptor: e

20050250817 - Pharmaceutical compositions of lipase-containing products, in particular of pancreation: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain...

20050250818 - Ortho substituted aryl or heteroaryl amide compounds: X represents a carbon atom or the like: Y represents imino, or the like: Z represents a hydrogen atom or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds...

20050250819 - Inhibitors of bacterial type iii protein secretion systems: In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial...

20050250820 - Therapeutic modulation of ppargamma activity: Modulators of PPARγ activity are used in methods of treating and/or preventing conditions such as osteoporosis, Alzheimer's disease, psoriasis and acne, and cancer....

20050250821 - Quaternary ammonium compounds in the treatment of water and as antimicrobial wash: Low levels of quaternary ammonium compounds are effective antimicrobial agents in drinking water and potentiate the antimicrobial power of organic acids used as antimicrobials for such purposes. The method is effective against both Gram (−) and Gram (+) bacteria, including but not limited to, Salmonella sp., E. coli, Campylobacter sp....

20050250823 - Gyrase inhibitors: Compounds comprising an indazolyl group and a thiazolyl group, preferably 7-substituted 3-(thiazol-2-yl)-1H-indazole compounds in which the indazolyl group and a thiazolyl group are each independently optionally substituted, are useful for the treatment or prophylaxis of bacterial infections in mammals. The compounds are believed to function by inhibiting gyrase B....

20050250822 - Substituted benzanilide compound and noxious organism controlling agent: wherein G represents a ring such as G-7, G-13 and G-71, etc., W1 and W2 each independently represent oxygen atom or sulfur atom, X represents halogen atom, etc., Y represents C1 to C6 alkyl, etc., R1, R2 and R3 each independently represent hydrogen atom, a C1 to C12 alkyl or...

20050250824 - Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient: (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating...

20050250825 - Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (H), is saturated or may contain a carbon-carbon double bond, while...

20050250826 - Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor: m

20050250828 - Candesartan cilexetil polymorphs: Provided are candesartan cilexetil forms and methods of their preparation. Also provided are pharmaceutical compositions prepared by combining at least one pharmaceutically-acceptable excipient with at least one candesartan cilexetil form of the invention....

20050250827 - Preparation of candesartan cilexetil in high purity: The present invention is directed to the preparation of substantially pure candesartan cilexetil by the deprotection of trityl candesartan cilexetil and crystallization and/or recrystallization of candesartan cilexetil....

20050250830 - Glycoluril core molecules for combinatorial libraries: The present invention provides novel glycoluril derivatives for use as core molecules in combinatorial chemistry. Core molecules of the present invention can contain from one to six building blocks. Preferred building blocks are substituted amine radicals. Combinatorial libraries containing such core molecules are also provided....

20050250829 - Kinase inhibitors: The invention relates to compounds comprising the below formula that may be used to inhibit kinases as well as compositions of matter, kits and methods comprising these compounds....

20050250833 - Derivatives of n-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators: Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed....

20050250832 - Novel benzimidazol-2-one derivatives and their use: The present invention provides novel benzimidazol-2-one derivatives useful as therapeutic agents....

20050250831 - Peroxisome proliferator activated receptor modulators: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula 1: and pharmaceutically acceptable salts thereof, wherein: (a) W is selected from the group consisting of O, C, N and S: (b) Z is an aliphatic linker wherein one carbon atom...

20050250834 - Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them: The present invention relates to novel tetracyclic arylcarbonyl indoles, their derivatives, their analogues, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, novel intermediates described herein and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel tetracyclic arylcarbonyl indoles of the general...

20050250836 - Inhibitors of checkpoint kinases (wee1 and chk1): This invention relates to substituted indacene molecules that specifically inhibit one or both of the checkpoint kinases Wee1 and Chk1 and are useful in the treatment of proliferative disorders....

20050250835 - Novel tumor-selective chemotherapeutic agents: The present invention relates to novel CC-1065 derivatives that bind to albumin in vitro and in vivo forming albumin-drug conjugates, and their methods of preparation and use as antitumor agents....

20050250837 - Use of c-raf inhibitors for the treatment of neurodegenerative diseases: C-Raf inhibitors, especially oxindole derivatives such as 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone, are used for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury. C-Raf inhibitors are included in the manufacture...

20050250838 - Formulation for sustained delivery: Disclosed is an extended or controlled release dosage form of citalopram or its related forms and other newer antidepressants for oral administration to treat chronic patients suffering from depression and to minimize the side effects associated with the current drug treatment....

20050250839 - Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods...

20050250840 - Mycophenolate mofetil in diabetic nephropathy: The present invention relates to a method of treating diabetic nephropathy with a combination of an immunosuppressive agent and an ACE inhibitor....

20050250841 - Autoinducer molecule: Autoinducer molecules, e.g., N-(3-oxododecanoyl)homoserine lactone, for Pseudomonas aeruginosa are described. The molecules regulate gene expression in the bacterium. Therapeutic compositions and therapeutic methods involving analogs and/or inhibitors of the autoinducer molecules also are described. The molecules are useful for treating or preventing infection by Pseudomonas aeruginosa....

20050250842 - Fungicidal mixtures: t

20050250843 - Medicinal compositions improving brain function and method for improving brain function: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function....

20050250844 - Methods of treating cancer using c-4 carbonate taxanes: A process for the preparation of novel C-4 carbonate taxanes useful as antitumor agents....

20050250845 - Pseudopolymorphic forms of a hiv protease inhibitor: New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed....

20050250846 - Non-peptide gnrh agents, pharmaceutical compositions and methods for their use: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for...

20050250847 - Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain: wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl...

20050250848 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers: The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs....

20050250849 - Basic amino acid - methionine hydroxy analog compositions: Simple, cost-effective and convenient compositions comprising basic amino acids and 2-hydroxy-4-methylthiobutanoic acid (HMBA) are disclosed. The compositions have many uses, including as food supplements for animal and human food....

20050250850 - Amino acid composition promoting collagen synthesis: Herein are disclosed an excellent collagen synthesis-promoting amino acid composition that are characterized by containing specific amino acids at a specific ratio, more specifically, by containing 10-40 parts by weight of L-arginine and/or 10-40 parts by weight of L-glutamine, as well as 5-20 parts by weight of L-valine, 8-30 parts...

20050250851 - Methods for treating neuropsychiatric disorders: The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, closed head injury, and attention deficit disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of...

20050250852 - Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target....

20050250853 - Beta-tubulin inhibitors: e

20050250854 - Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent....

20050250855 - Compounds for treating human papillomavirus: Methods and compositions for treating human papillomavirus infections are described....

20050245431 - Membrane, device and method for removing proteases from liquids: The invention comprises a membrane and device and method for removing proteases from fluids, particularly from biological fluids and pharmaceutical solutions, which uses a microporous membrane body, whereby inhibitors that selectively bind proteases are coupled to the membrane body by chemically activated groups....

20050245432 - N-methyl amino acids: The present invention relates to a compound of formula (I) or (II), processes for preparing them, peptides including them and kits involving them....

20050245433 - Materials and methods for modulating metabolism: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound...

20050245435 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds....

20050245434 - Oxygenated dibenzo-alpha-pyrone chromoproteins: A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as...

20050245436 - Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons...

20050245437 - Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs: e

20050245439 - Prevention of joint destruction: A method for treating, preventing or reducing the risk of joint destruction in a subject who suffers from a joint or musculoskeletal disease. The method comprises administering a histone deacetylase (HDAC) inhibitor or in conjunction with other agents to inhibit degradation and resorption of cartilage and bone in the joint....

20050245438 - Receptor(sstr4)-selective somatostatin analogs: Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA1,2,4,5,12,13[Ala7]-SRIF; des-AA1,2,4,5,12,13[Aph7]-SRIF, des-AA1,2,4,5,12,13[Aph7]Cbm-SRIF; des-AA1,2,4,5,12,13[Tyr2,Ala7]-Cbm-SRIF, and des-AA1,2,4,5,12,13[Tyr7,CβMe-L-2Nal8]-SRIF, and counterparts incorporating...

20050245443 - Bacteria strain and bacteriocin produced therefrom: The present invention concerns an isolated bacteriocin, Divergicin M35, derived form Carnobacterium divergens M35. It also concerns a composition comprising an effective amount of Divergicin M35 and the use of that bacteriocin to kill or limit the proliferation of a microorganism....

20050245448 - Dtat fusion toxin: The invention provides fusion toxins that contain one or more regions of diphtheria toxin and a portion of urokinase-type plasminogen activator, as well as the nucleic acids that encode the fusion toxins and methods of using the fusion toxins....

20050245446 - Materials for the delivery of biologically-active material to cells: wherein X1, X2 and R1 to R5 are as defined herein. Such lipids are used to form complexes with a biologically-active material such as a nucleic acid, peptide or small molecule for delivering the biologically-active material to cells. The complexes may incorporate an integrin-binding peptide and, when the biologically-active material...

20050245450 - Method of screening a compound for anxiolytic activity in an apolipoprotein e knockout animal: Methods and compositions for use in treating anxiety are provided. In the subject methods, an effective amount of an agent having ApoE3 activity is administered to a host suffering from an anxiety, e.g. excessive anxiety, unwanted anxiety, an anxiety disorder, etc. Also provided are methods and compositions for modulating adrenal...

20050245444 - Method of using recombinant human antithrombin for neurocognitive disorders: The present invention provides for the production of recombinant human antithrombin (rhAT) for the treatment or prophylaxis of neurocognitive disorders typically associated with major surgical procedures. The recombinant processes of the current invention as well as more efficient methods of treatment, formulation and production have been developed to treat the...

20050245449 - Methods for modifying cell motility using factor viia antagonist: A novel intracellular signalling activity of coagulation factor VII (FVII) in cells expressing tissue factor (TF) is described. The present invention relates to use of FVIIa or another TF agonist, or FVIIai or another TF antagonist for the preparation of a medicament for modulation of FVIIa-induced activation of the MAPK...

20050245447 - Modified chimeric polypeptides with improved pharmacokinetic properties and methods of making and using thereof: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides...

20050245445 - Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs: The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID...

20050245440 - Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2: New methods of screening for compounds for treating colon cancer are described. Using microarray expression profiling, molecular evidence was obtained supporting lack of differentiation as the mechanism for development of colon polyps and tumors. An absence of retinoic acid (RA) response genes from neoplastic tissue colon tissues was observed. The...

20050245442 - Steroid conjugates, preparation thereof and the use thereof: Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and haematological malignancies. Further the conjugates exhibits a synergistic action together with a cytoskeleton acting drug such as Taxol®, which enable the treatment of...

20050245441 - Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity: Use of a compound having 50% activity or more of the activity of gastric inhibitory polypeptide, GIP, when tested in the same assay under the same conditions, and/or the use of GIP, analogues and fragments thereof, for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of conditions caused...

20050245451 - Peptides selectively lethal to malignant and transformed mammalian cells: The present invention provides peptides corresponding to all or a portion of amino acid residues 12-26 of human p53 protein, which peptides are lethal to malignant or transformed cells when fused to a membrane-penetrating leader sequence. In order to reduce proteolysis of a subject peptide, one or more D-amino acids...

20050245452 - Pharmaceutical use of novispirins: The present invention relates to use of Novispirin antimicrobial polypeptides in preparation of a pharmaceutical composition suitable for use against microbial lung infections or skin infections or for use in promoting wound healing....

20050245454 - Methods and compositions for impairing multiplication of hiv-1: A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y7-Leu-X9-Pro-Trp-Z12-R2 (SEQ ID NO: 8)....

20050245453 - Peptides derived from cadherin and methods of use thereof: The present invention provides polypeptides and peptides derived from cadherin. The polypeptides and peptides are useful in a method of inhibiting amyloid deposition and a method of inhibiting tumor metastasis. A method of determining susceptibility to Alzheimer's disease and a method of screening for agents that modify cadherin processing are...

20050245455 - Gonadotropin releasing hormone antagonists in gel-forming concentrations: Pharmaceutical compositions are provided for the treatment of steroid-dependent and other diseases. The compositions are solutions for subcutaneous or intramuscular injection, and the active agent is a GnRH antagonist peptide according to general formula (1): Ac-DNal-DCpa-DPal-Ser-Aph(X1)-DAph(X2)-Leu-Lys(iPr)-Pro-DAla-NH2 present at a concentration sufficient to from a gel following administration....

20050245456 - Combination therapy to prevent and treat diarrhea induced by cancer treatment: This invention relates to a method of treating drug side effects in cancer treatment. More particularly, the present invention relates to preventing, reducing, alleviating, or reversing diarrhea caused by the administration of the isothiazole 3-(4-Bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide in the treatment of cancer comprising the step of administering to a patient...

20050245458 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease....

20050245457 - Pseudopeptides growth hormone secretagogues: The present invention relates to novel growth hormone releasing pseudopeptides capable of stimulating the release of growth hormone from the pituitary and of promoting growth in mammals. The invention also provides pharmaceutical compositions comprising the pseudopeptides growth hormone secretagogues and a method for promoting the release of growth hormone in...

20050245459 - Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide: A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of...

20050245460 - Methods and compositions for the treatment of epilepsy, seizure disorders, and other cns disorders: The present invention relates to methods and compositions for treating CNS-related disorders....

20050245461 - Methods for treating alcoholism: In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention...

20050245462 - Treatment of cancer with 2-deoxyglucose: The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy....

20050245463 - Novel antiretroviral sulfolipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the hiv virus reverse transcriptase: The invention relates to novel sulfolipids extracted from spirulins, to the process for obtaining them, to the compositions containing them and to their use as HIV-1 and HIV-2 inhibitors. The invention further relates to a spirulin biomass rich in sulfolipids which has an inhibitory activity towards HIV-1 and HIV-2 reverse...

20050245464 - Use of lipid conjugates in the treatment of diseases: This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or...

20050245465 - Compounds for treating alzheimer's disease and for inhibiting beta-amyloid peptitde production: The present invention provides compositions and methods for treating and preventing Alzheimer's disease by administering to a subject an effective amount of a dammarane or ginsenoside compound. The invention also provides compositions and methods for modulating beta-amyloid protein production, including Aβ42 in a cell. The invention further provides compositions and...

20050245467 - Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract: The present invention relates to methods of treating conditions and/or symptoms related to common cold of the upper and/or lower respiratory tract and/or eyes. In particular the invention relates to the methods of treating conditions and/or symptoms related to common cold comprising administration of a flavonoid or administration of a...

20050245466 - Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy: The present invention relates to the use of a first agent that attenuates topoisomerase II (Topo II) activity and a second agent that inhibits Heat Shock Protein 90 (HSP90) for use in chemotherapy. The agents are particularly useful in the treatment of cancer and destruction of micro-organisms. The invention also...

20050245468 - Anthelmintic composition: The present invention provides an anthelmintic composition including an avermectin or milbemycin, together with triclabendazole, and a predetermined quantity of rheology modifier, such as Laponite or xanthan gum, sufficient to render the anthelmintic composition suitable as an oral drench....

20050245469 - Crystal forms of azithromycin: The invention relates to novel crystal forms of azithromycin, an antibiotic useful in the treatment of infections....

20050245470 - Anticancer biangeloyl saponins: Novel compounds such as compounds designated herein as Y or Y3, Y1, Y2, Y8, Y9 and Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products. The compounds...

20050245471 - Combination products for use in antitumoral treatment: The invention concerns combination products comprising (i) at least a substance capable of inhibiting CSF-1 activity and/or at least a nucleic acid, comprising at least a sequence coding for a substance capable of inhibiting CSF-1 activity and (ii) at least a substance having a cytotoxic activity and/or at least a...

20050245474 - Double stranded constructs comprising one or more short strands hybridized to a longer strand: The present invention provides compositions comprising an antisense oligomeric compound hybridized to at least one shorter sense oligomeric compound. The sense oligomeric compounds can be covalently linked to the antisense oligomeric compounds. At least a portion of the antisense oligomeric compound is complementary to and hybridizes with a nucleic acid...

20050245472 - Engineered rnai adenovirus silencing expression (erase) of dna reair proteins: The present invention relates to compositions and methods for killing cancer cells and treating subjects having cancer comprising administering small inhibitory RNAs (siRNA) specific for DNA repair proteins in conjunction with administration of conventional DNA-damaging agents such as radiation and chemotherapeutic agents....

20050245475 - Functional and hyperfunctional sirna directed against bcl-2: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes....

20050245477 - Immunomodulatory oligonucleotides: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides...

20050245473 - Proliferation- and differentiation-modulating agents and uses therefor: The present invention discloses the use of E2F pathway modulators and optionally a differentiation stimulus in methods for treating or preventing conditions associated with the deregulation of epithelial cell proliferation and differentiation and for diagnosing the presence or risk of developing such conditions....

20050245476 - Treatment of neuropathic pain with zinc finger proteins: A variety of zinc finger proteins (ZFPs) and methods utilizing such proteins are provided for use in treating neuropathic pain. ZFPs that bind to a target site in genes that are aberrantly expressed in subjects having neuropathic pain are described. In addition, ZFPs that bind to a target site in...

20050245478 - Postoperative adjuvant chemotherapy with uft: The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients....

20050245481 - Method of producing teicoplanin: Disclosed is a method of producing teicoplanin. The method includes purifying teicoplanin from a culture broth, obtained by culturing microorganisms capable of producing teicoplanin by a porous adsorption resin under selective elution conditions and recovering highly pure teicoplanin using activated carbon and/or ultrafiltration. In this regard, the method can further...

20050245480 - Methods of using beta glucan as a radioprotective agent: The invention relates to methods for treating and preventing radiation and/or chemotherapy related injury and/or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided...

20050245479 - Myeloglycan: Systematic chemical analysis of glycosphingolipid (GSL) fractions from large quantities of normal human neutrophils and HL60 cells failed to detect GSL's which are binding targets of selectin. A series of long-chain, unbranched polylactosamine GSL's with a terminally sialylated, internally polyfucosylated structure bind selectins....

20050245482 - Chitosan and method of preparing chitosan: A highly deacetylated chitosan obtained from microbial biomass, a method of obtaining chitosan from microbial biomass, and biomass for making chitosan are disclosed. The method includes providing chitin-containing biomass; reacting the chitin-containing biomass in a caustic solution of greater than 25 percent alkali at a reaction temperature greater than 95°...

20050245484 - Lubricious germicidal ophthalmic solutions: A novel class of lubricious ophthalmic solutions is formulated to permit the use of a recognized class of demulcents; namely, anionic polymeric demulcents in the presence of a cationic quaternary germicide wherein no precipitation of said germicide occurs....

20050245483 - Matrix for sustained, invariant and independent release of active compounds: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics...

20050245485 - Novel indole derivatives as selective androgen receptor modulators (sarms): The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor....

20050245486 - Modified psma ligands and uses related thereto: The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA....

20050245487 - Mitochondrially targeted antioxidants: The invention provides mitochondrially targeted antioxidant compounds. A compound of the invention comprises a lipophilic cation covalently coupled to an antioxidant moiety. In preferred embodiments, the lipophilic cation is the triphenyl phosphonium cation, and the compound is of the formula P(Ph3)+XR.Z− where X is a linking group, Z is an...

20050245488 - Pharmaceutically active compounds and methods of use thereof: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treatment or prophylaxis of undesired thrombosis....

20050245489 - Chromene-containing compounds with anti-tubulin and vascular targeting activity: Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove...

20050245490 - Chromene-containing compounds with anti-tubulin and vascular targeting activity: Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove...

20050245491 - Tetracycline derivatives and methods of use thereof: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives....

20050245492 - Use of equol for treating skin diseases: Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These...

20050245494 - Methods to treat one or all of the defined etiologies of female sexual dysfunction: The U.S. Food and Drug Administration defines the four separate components of Female Sexual Dysfunction (FSD) to be decreased sexual desire, decreased sexual arousal, dyspareunia (pain with intercourse), and persistent difficulty in achieving or inability to achieve orgasm (anorgasmia). To establish a diagnosis of FSD, these components must be associated...

20050245493 - Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis: The present invention relates to a combination of ciclesonide with antihistamines....

20050245495 - Azacyclosteroid histamine-3 receptor ligands: Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein....

20050245496 - High-purity composition comprising (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one and a process for purifying (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one: The invention pertains to a process for the preparation of a high-purity composition of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one. The process provides for a composition with less than 0.5% of (7α, 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one. This composition can be used as a source for the preparation of stable pharmaceutical dosage units....

20050245497 - Treatment of ophthalmic conditions: The present invention provides a method of treatment of an individual with an ophthalmic condition that may comprise the step of: administering to the individual a therapeutically effective amount of a compound capable of modulating the activity of mineralocorticoid receptors within cells or tissue located in an eye or adjacent...

20050245498 - Sterically-awkward beta-lactamase inhibitors: Sterically-awkward 6-β-substituted P-lactam compounds as inhibitors of β-lactamase activity, such compounds as can be used in conjunction with one or more β-lactam antibiotics in a system for treatment of a β-lactam resistant bacterial infection....

20050245499 - Heterocyclic protein kinase inhibitors and uses thereof: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such...

20050245500 - Beta-ketoamide compounds with mch antagonistic activity: wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical...

20050245501 - Succinoylamino lactams as inhibitors of a-beta protein production: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly,...

20050245502 - Treatments for viral infections: The present invention relates to improved methods and compositions for treating viral infections. More particularly, the present invention relates to novel compositions comprising an anti-convulsant, such as phenytoin, in combination with multivitamins as an anti-viral composition and methods of use thereof....

20050245503 - Therapeutic heterocycles: Compounds of formula (I) or (II) wherein R1, R2, R3, R4, W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20050245504 - Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds: The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase....

20050245505 - Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents: e

20050245506 - Treatment of congestive heart failure:

20050245507 - 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents: R7 and R8 each independently represent hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or...

20050245508 - Treatment of malignant gliomas with tgf-beta inhibitors: The invention concerns methods of treating malignant gliomas, by administering inhibitors of TGF-β the TGF-β signaling pathway, including molecules preferably binding to the type I TGF-β receptor (TGFβ-R1). Preferably, the inhibitors are non-peptide small molecules, including quinazoline derivatives. The invention also concerns methods for reversing the TGF-β-mediated effect on glioma...

20050245509 - Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor and prostaglandins as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with prostaglandins. For the administration mode, each...

20050245510 - Use of meloxicam formulations in veterinary medicine: The invention is directed to the use of a formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base, one or more vehicles and one or more suitable additives for preparing a veterinary medical composition for intramammary treatment of inflammatory diseases in mammals, particularly mastitis....

20050245511 - Novel compounds that inhibit tryptase activity: e

20050245512 - Method and composition for rejuvinating cells, tissues organs, hair and nails: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce...

20050245513 - Hetero-bridge substituted 8-arylquinoline pde4 inhibitors: 8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors....

20050245515 - Indolyl derivatives as liver-x-receptor (lxr) modulators: a

20050245514 - Novel physiologically active substances:

20050245516 - Process for imidazo[4,5-c]pyridin-4-amines: A process and intermediates for preparing 1H-imidazo[4,5-c]pyridin-4-amines are disclosed. The process includes providing a 7H-imidazo[4,5-c]tetrazolo[1,5-a]pyridine and converting a 7H-imidazo[4,5-c]tetrazolo[1,5-a]pyridine to a 1H-imidazo[4,5-c]pyridin-4-amine....

20050245517 - 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I to modulate GABA and GABAA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive...

20050245518 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions....

20050245519 - Substituted morpholine compounds for the treatment of central nervous system disorders: e

20050245520 - 2-phenylpyridin-4-yl derivatives as alk5 inhibitors: This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, (“TGF”)-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment...

20050245521 - Novel benayl(idene)-lactam derivatives: wherein R1, R3, R6, R13 X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the...

20050245522 - Novel compounds: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of...

20050245523 - Heteroaryl derivatives and their use as medicaments: The invention relates to novel quinoline derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for treating tumors....

20050245524 - Benzotriazine inhibitors of kinases: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases....

20050245525 - Compounds useful for inhibiting chk1: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome...

20050245526 - Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions: wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and...

20050245527 - Nitrogen containing heterocyclic compounds and medicines containing the same: e

20050245528 - Reverse-turn mimetics and compositions and methods related thereto: wherein A, R1, R2, R2a and R3 are as defined herein. Such compounds have utility over a wide range of fields, including use as diagnostic and therapeutic agents. In particular, compounds of this invention are useful in pharmaceutical compositions as anti-inflammatory agents as well as inhibitors of central nervous disorders....

20050245529 - Alkyne compounds with mch antagonistic activity and medicaments comprising these compounds: e

20050245530 - Monocyclic heterocycles as kinase inhibitors:

20050245531 - Fused bicycloheterocycle substituted quinuclidine derivatives: wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed...

20050245534 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other...

20050245532 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme and their therapeutic application: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic...

20050245533 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenasetype 1 enzyme and their therapeutic application: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic...

20050245535 - Sulfonyl amide inhibitors of calcium channel function: e

20050245536 - Cytokine inhibitors:

20050245537 - Use of compounds having ccr antagonism: It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone...

20050245538 - Proline derivatives and use thereof as drugs:

20050245539 - Pharmaceutical compositions for the treatment of sexual disorders ii: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of...

20050245540 - New methods: e

20050245541 - Methods for treating alcoholism: In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention...

20050245542 - Pyridazine, pyrimidine and pyrazine ethyne compounds: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent...

20050245543 - Histamine-3 receptor antagonists: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound...

20050245544 - Novel pharmaceuticals: This invention relates to compounds of formula (I)...

20050245546 - A1 adenosine receptor antagonists: Disclosed are A1adenosine receptor antagonists, useful for treating various disease states, in particular disease states for which diuretic treatment is appropriate....

20050245545 - Adenosine a2s receptor antagonists for treating restless legs syndrome or related disorders: The present invention provides methods of treating restless legs syndrome or related disorders, comprising administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof. More preferably the adenosine A2A receptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof....

20050245547 - Compounds and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention...

20050245548 - Alkynylated fused ring pyrimidine compounds: l

20050245549 - Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor,...

20050245550 - Fungicidal mixtures based on the dithianon: e

20050245551 - Amide derivatives: The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and...

20050245553 - Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives: e

20050245552 - N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis:

20050245554 - Substituted pyrimidines: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,...

20050245555 - Tri-substituted ureas as cytokine inhibitors: The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for...

20050245557 - Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain: Methods and materials, including novel compositions, dosage forms and methods of administration, useful for treating arthritic conditions, inflammation associated with a chronic condition, and/or chronic pain, including pain from arthritis and inflammation, using opioid antagonists, including combinations of opioid antagonists and opioid agonists. Methods and materials comprising opioid antagonists or...

20050245558 - Naltrexone long acting formulations and methods of use: The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use...

20050245556 - Pharmaceutical preparation containing oxycodone and naloxone: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy with the active compounds being released from the preparation in a sustained, invariant and independent manner....

20050245559 - Treatment and prevention of prostate cancer: The present invention provides novel methods of preventing and treating prostate cancer with tetrandrine, a bisphehol-isoquinoline alkaloid isolated from the Chinese herb Stephania tetrandra. The present invention also provides the use of tetrandrine for the manufacture of a pharmaceutical composition for treating prostate cancer. The tetrandrine can be used as...

20050245560 - Preparation of cabergoline: The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing cabergoline form I by combining cabergoline and a first solvent to form a...

20050245561 - Anti-tumour polycyclic carboxamides: This invention relates to polycyclic carboxamide compounds of the formula (I) with cytotoxicity, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly I the treatment and/or prophylaxis of cellular proliferative disorders such a cancer....

20050245562 - 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases: The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases,...

20050245563 - Chk-1 inhibitors: Disclosed are novel inhibitors of Chk-1 and methods of using the same for therapy....

20050245564 - Methods and compositions related to irm compounds and toll-like receptor pathways: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and...

20050245565 - Diamine derivatives: The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS),...

20050245566 - Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones: e

20050245567 - Novel quinuclidine derivatives and their use: This invention relates to novel quinuclidine derivatives and their use as pharmaceuticals. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous...

20050245568 - Process for making montelukast and intermediates therefor: i

20050245569 - Process for making montelukast and intermediates therefor:

20050245570 - 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels...

20050245571 - Amine derivative: wherein X and X′ are the same or different and each represents a hydrogen atom, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrocarbon group optionally having substituents, etc.; R4 represents a hydrogen atom, etc.; Y and Ya are...

20050245574 - Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof: e

20050245573 - N-substituted benzene sulfonamides:

20050245572 - Naphthyl ether compounds and their use: Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same....

20050245575 - 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists: The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included....

20050245576 - Substituted pyrazoles: Substituted pyrazoles, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S are described....

20050245577 - Drug for kidney failure containing oxaluric acid derivative: The effective ingredient of the agent for renal failure of the present invention is an oxaluric acid derivative having an excellent suppressive effect of the progression of renal failure. The oxaluric acid derivatives of the present invention have an excellent suppressive effect of the progression of renal failure to inhibit...

20050245578 - Polymorphs of pantoprazole sodium salt and process for the preparation thereof: Novel crystalline forms of pantoprazole sodium salt solvate with ketone solvents, a process for the preparation thereof, the use of the forms for the purification of pantoprazol, pharmaceutical compositions therefrom and the use thereof in therapy....

20050245579 - Iron binding agents: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention...

20050245580 - Novel substituted dihydro 3-halo-1h-pyrazole-t-carboxylates, their preparation and use: m

20050245581 - 1, 2-dihydropyridine compounds, manufacturing method thereof and use thereof: In the formula, Q indicates NH, O or S; and R1, R2, R3, R4 and R5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C1-6 alkyl group or a group represented by the formula —X-A (wherein X indicates a single...

20050245582 - High concentration topical insecticides containing pyrethroids: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth...

20050245583 - 4-(3,3-dihalo-allyloxy)phenoxy alkyl derivatives: R7 is H, C1-C6alkyl, C1-C6alkoxyalkyl or C1-C6alkylcarbonyl; k, when D is nitrogen, is 1, 2 or 3; or, when D is CH, is 1, 2, 3 or 4; and m is 1 or 2; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in...

20050245584 - Peroxisome proliferator activated receptor agonists: Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl,...

20050245585 - Process for preparing optically pure zolmitriptan: A process for preparing zolmitriptan, proceeding through the intermediate Ethyl-3-[2-(1,3-dioxo-2,3-dihydro-1H-2-isoindoleyl)ethyl]-5-[(4S)-2-oxo-1,3-oxazolan-4-ylmethyl]-1H-2-indole carboxylate....

20050245586 - 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12: The invention provides compounds of formula (I) in which L, X, Y, Z1, Z2, R1, R2, R3 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds of the...

20050245587 - Treatment of dyskinesia: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy....

20050245588 - Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators: The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included....

20050245589 - Pyrazole phenyl derivatives: and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are...

20050245590 - Crystalline forms of imidoalkanpercarboxylic acids: Imidoalkancarboxylic acids of formula (I) are described, wherein A, X and M are as defined in the application, said acids being in a crystalline form which in contact with water gives rise to crystals having sizes lower than 30 micron....

20050245591 - Process: The present invention provides an improved process for the preparation of α-polymorphic eletriptan hydrobromide....

20050245592 - 2-iminopyrrolidine derivatives: e

20050245593 - 4-aminomethyl-1-aryl-cyclohexylamine compounds: The invention concerns 4-aminomethyl-1-aryl-cyclohexylamine compounds, methods for producing same, pharmaceutical formulations containing said compounds and the use of 4-aminomethyyl-1-aryl-cyclohexylamine compounds for producing medicines and in related methods of treatment....

20050245594 - Dermal delivery of anti-pain agents and methods useful thereof: The present invention relates to methods and devices for delivery of therapeutically and/or prophylactically effective amounts of agents for management of pain, particularly anti-migraine agents, more particularly triptan compounds, by depositing the agent into the intradermal or junctional compartment of a subject's skin. Agents delivered in accordance with the methods...

20050245595 - Positive modulators of nicotinic receptor agonists: e

20050245596 - Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss: Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using...

20050245597 - Stable hydrate of a muscarinic receptor antagonist: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage,...

20050245598 - Bafilomycin-like metabolite from a novel micromonospora species: The invention provides a compound of formula (I) and pharmaceutically acceptable salts thereof. Processes for the isolating of this bafilomycin metabolite from a novel Micromonospora species, pharmaceutical compositions containing this metabolite and methods of treatment using said metabolite are also described...

20050245599 - Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier...

20050245600 - Novel antimalarial agent: A novel antimalarial agent. It is a medical composition comprising a pharmaceutically acceptable carrier and a compound represented by the general formula (I), wherein R1 to R12 is independently, hydrogen, halogen, hydroxy, alkyl, alkoxy, amino or acylamino....

20050245602 - Selective estrogen receptor modulators: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration;...

20050245601 - Treatment of diseases involving erbb2 kinase overexpression: This invention relates to compositions containing polyphenols such as flavanols and their related oligomers, and methods for treating conditions associated with ErbB2 kinase overexpression, for example, treatment of cancers involving ErbB2 kinase overexpression....

20050245603 - Materials and methods for treating coagulation disorders: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The...

20050245604 - Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester: A compound having formula (I) and a process for the preparation thereof are described....

20050245605 - Anhydrous silver dihydrogen citrate compositions: Anhydrous silver dihydrogen citrate compositions comprise silver dihydrogen citrate and citric acid. The anhydrous compositions can be prepared by freeze-drying. The anhydrous compositions can be reconstituted with a suitable diluent to form silver dihydrogen citrate compositions. The anhydrous compositions can be reconstituted and applied to a variety of substrates to...

20050245606 - High-efficiency fullerene-based radical scavengers: Chemically functionalized fullerenes are useful in various applications as radical scavengers. These chemically functionalized fullerenes offer the advantages of preservation of the high innate radical scavenging efficiency of the fullerene cage and ease of synthesis of fullerene derivatives of desirably altered chemical and physical properties and single isomers. Further, they...

20050245607 - N-bisaryl- and n-aryl-cylcloakylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides: The invention relates to N-bisaryl- and N-aryl-cycloalkylidenyl-a-hydroxy- and a-alkoxy acetic acid amides of the general formula (I) including the optical isomers thereof and mixtures of such isomers, wherein R1 is hydrogen, C1-C12alkyl; C2-C12alkenyl; C2-C12alkynyl; C1-C12haloalkyl; R2 is hydrogen; optionally substituted alkyl; optionally substituted alkenyl or optionally substituted alkynyl; R3 is...

20050245608 - Compositions with anisic acid and glycerides: This invention relates to formulations containing a combination of anisic acid, or a salt thereof, or an ester thereof, and a C6-14 fatty acid monoglyceride and to the use of such combinations as a preservative system....

20050245609 - Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions: This invention is directed to a method of using a therapeutic composition comprising an ester of an alpha-ketoalkanoic acid for the treatment of cytokine-mediated inflammatory conditions. The cytokine-mediated inflammatory conditions are mediated by, for example, Tumor Necrosis Factor (TNF), interleukin-1β (IL-1β)) or High Mobility Group B-1 (HMGB-1) mediator of inflammation....

20050245610 - Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease: A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of...

20050245611 - Intravenous valproate for acute treatment of migraine headache: The present invention features a novel therapy for effecting acute treatment of migraine headache. The therapy involves intravenous administration of valproate and is equal to and in some respects superior to previously-known therapies for abortive treatment of prolonged moderate to severe acute migraine headache....

20050245612 - Pharmaceutical compositions for metabolic insufficiencies: Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof....

20050245613 - Use of gaba-b receptor positive modulators in gastro-intestinal disorders: The invention relates to the use of a compound acting as positive allosteric modulator of GABAB receptors in the treatment of GERD, regurgitation, IBS, dyspepsia, postoperative complaints and conditions associated with visceral discomfort/pain....

20050245614 - Tranexamic acid formulations: Disclosed are oral tranexamic acid formulations and methods of treatment therewith....

20050245615 - Composition containing polyamine transport inhibitor and use thereof: s

20050245616 - Compounds and related methods for mutant p53 reactivation: Ketoamine compounds and related methods for reactivation of tumor suppressor protein p53....

20050245617 - Methods and compositions for the treatment of cns-related conditions: The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease....

20050245618 - Lubricious ophthalmic solutions: There are provided lubricious ophthalmic solutions having a pH of between about 7.0 and about 8.0, consisting essentially of an aqueous solution of from about 0.5-4% by weight of a monographed polyol, borate calculated as the borate equivalent of 20-100% by weight of boric acid relative to said polyol, from...